{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "P95DxvqWi_2Y"
   },
   "source": [
    "#### For Colab"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 0
    },
    "executionInfo": {
     "elapsed": 861,
     "status": "ok",
     "timestamp": 1610380362544,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "GD_KFnI1H1ip",
    "outputId": "91b83ff6-dcb3-4452-c2d3-957a0a539237"
   },
   "outputs": [
    {
     "data": {
      "application/vnd.google.colaboratory.intrinsic+json": {
       "type": "string"
      },
      "text/plain": [
       "'\\nfunction ClickConnect(){\\n    console.log(\"Working\");\\n    document.querySelector(\"colab-toolbar-button\").click() \\n}\\nvar i = setInterval(ClickConnect, 900000)\\nclearInterval(i)\\n'"
      ]
     },
     "execution_count": 49,
     "metadata": {
      "tags": []
     },
     "output_type": "execute_result"
    }
   ],
   "source": [
    "\"\"\"\n",
    "function ClickConnect(){\n",
    "    console.log(\"Working\");\n",
    "    document.querySelector(\"colab-toolbar-button\").click() \n",
    "}\n",
    "var i = setInterval(ClickConnect, 900000)\n",
    "clearInterval(i)\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 2459,
     "status": "ok",
     "timestamp": 1610380364156,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "RR-OcN_Wy1jE",
    "outputId": "4c8f528f-a9f6-4112-9d77-93fac1930623"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Mounted at /content/drive\n"
     ]
    }
   ],
   "source": [
    "from google.colab import drive\n",
    "drive.mount('/content/drive', force_remount=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {
    "executionInfo": {
     "elapsed": 2455,
     "status": "ok",
     "timestamp": 1610380364159,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "au5Z9XQAC7C-"
   },
   "outputs": [],
   "source": [
    "drive_dir = '/content/drive/My Drive/MAGMA: Summarization/'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "tvSGvNzvKbvP"
   },
   "source": [
    "#### Install Libraries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 14725,
     "status": "ok",
     "timestamp": 1610379158847,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "Ld3WDPaf9Saw",
    "outputId": "9b9ce95e-8826-457c-ac32-14f9a9b4455b"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Requirement already satisfied: transformers==4.1.1 in /usr/local/lib/python3.6/dist-packages (4.1.1)\n",
      "Requirement already satisfied: tokenizers==0.9.4 in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (0.9.4)\n",
      "Requirement already satisfied: tqdm>=4.27 in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (4.41.1)\n",
      "Requirement already satisfied: requests in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (2.23.0)\n",
      "Requirement already satisfied: dataclasses; python_version < \"3.7\" in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (0.8)\n",
      "Requirement already satisfied: filelock in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (3.0.12)\n",
      "Requirement already satisfied: packaging in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (20.8)\n",
      "Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (2019.12.20)\n",
      "Requirement already satisfied: numpy in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (1.19.4)\n",
      "Requirement already satisfied: sacremoses in /usr/local/lib/python3.6/dist-packages (from transformers==4.1.1) (0.0.43)\n",
      "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.6/dist-packages (from requests->transformers==4.1.1) (2.10)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.6/dist-packages (from requests->transformers==4.1.1) (2020.12.5)\n",
      "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.6/dist-packages (from requests->transformers==4.1.1) (3.0.4)\n",
      "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.6/dist-packages (from requests->transformers==4.1.1) (1.24.3)\n",
      "Requirement already satisfied: pyparsing>=2.0.2 in /usr/local/lib/python3.6/dist-packages (from packaging->transformers==4.1.1) (2.4.7)\n",
      "Requirement already satisfied: click in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers==4.1.1) (7.1.2)\n",
      "Requirement already satisfied: joblib in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers==4.1.1) (1.0.0)\n",
      "Requirement already satisfied: six in /usr/local/lib/python3.6/dist-packages (from sacremoses->transformers==4.1.1) (1.15.0)\n",
      "Requirement already up-to-date: sentencepiece!=0.1.92 in /usr/local/lib/python3.6/dist-packages (0.1.95)\n",
      "Requirement already up-to-date: datasets in /usr/local/lib/python3.6/dist-packages (1.2.0)\n",
      "Requirement already satisfied, skipping upgrade: requests>=2.19.0 in /usr/local/lib/python3.6/dist-packages (from datasets) (2.23.0)\n",
      "Requirement already satisfied, skipping upgrade: dill in /usr/local/lib/python3.6/dist-packages (from datasets) (0.3.3)\n",
      "Requirement already satisfied, skipping upgrade: dataclasses; python_version < \"3.7\" in /usr/local/lib/python3.6/dist-packages (from datasets) (0.8)\n",
      "Requirement already satisfied, skipping upgrade: numpy>=1.17 in /usr/local/lib/python3.6/dist-packages (from datasets) (1.19.4)\n",
      "Requirement already satisfied, skipping upgrade: tqdm<4.50.0,>=4.27 in /usr/local/lib/python3.6/dist-packages (from datasets) (4.41.1)\n",
      "Requirement already satisfied, skipping upgrade: xxhash in /usr/local/lib/python3.6/dist-packages (from datasets) (2.0.0)\n",
      "Requirement already satisfied, skipping upgrade: pandas in /usr/local/lib/python3.6/dist-packages (from datasets) (1.1.5)\n",
      "Requirement already satisfied, skipping upgrade: pyarrow>=0.17.1 in /usr/local/lib/python3.6/dist-packages (from datasets) (2.0.0)\n",
      "Requirement already satisfied, skipping upgrade: multiprocess in /usr/local/lib/python3.6/dist-packages (from datasets) (0.70.11.1)\n",
      "Requirement already satisfied, skipping upgrade: certifi>=2017.4.17 in /usr/local/lib/python3.6/dist-packages (from requests>=2.19.0->datasets) (2020.12.5)\n",
      "Requirement already satisfied, skipping upgrade: chardet<4,>=3.0.2 in /usr/local/lib/python3.6/dist-packages (from requests>=2.19.0->datasets) (3.0.4)\n",
      "Requirement already satisfied, skipping upgrade: idna<3,>=2.5 in /usr/local/lib/python3.6/dist-packages (from requests>=2.19.0->datasets) (2.10)\n",
      "Requirement already satisfied, skipping upgrade: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.6/dist-packages (from requests>=2.19.0->datasets) (1.24.3)\n",
      "Requirement already satisfied, skipping upgrade: python-dateutil>=2.7.3 in /usr/local/lib/python3.6/dist-packages (from pandas->datasets) (2.8.1)\n",
      "Requirement already satisfied, skipping upgrade: pytz>=2017.2 in /usr/local/lib/python3.6/dist-packages (from pandas->datasets) (2018.9)\n",
      "Requirement already satisfied, skipping upgrade: six>=1.5 in /usr/local/lib/python3.6/dist-packages (from python-dateutil>=2.7.3->pandas->datasets) (1.15.0)\n",
      "Requirement already satisfied: rouge_score in /usr/local/lib/python3.6/dist-packages (0.0.4)\n",
      "Requirement already satisfied: nltk in /usr/local/lib/python3.6/dist-packages (from rouge_score) (3.2.5)\n",
      "Requirement already satisfied: numpy in /usr/local/lib/python3.6/dist-packages (from rouge_score) (1.19.4)\n",
      "Requirement already satisfied: absl-py in /usr/local/lib/python3.6/dist-packages (from rouge_score) (0.10.0)\n",
      "Requirement already satisfied: six>=1.14.0 in /usr/local/lib/python3.6/dist-packages (from rouge_score) (1.15.0)\n"
     ]
    }
   ],
   "source": [
    "!pip install transformers==4.1.1\n",
    "!pip install -U sentencepiece!=0.1.92\n",
    "!pip install -U datasets\n",
    "!pip install rouge_score"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "S0FByNNOIRvG"
   },
   "source": [
    "### **Config**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {
    "executionInfo": {
     "elapsed": 930,
     "status": "ok",
     "timestamp": 1610380364161,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "3BHImWfNKpDN"
   },
   "outputs": [],
   "source": [
    "import os\n",
    "import sys\n",
    "\n",
    "sys.path.insert(0, drive_dir)\n",
    "import config\n",
    "\n",
    "from torch import cuda\n",
    "device = 'cuda' if cuda.is_available() else 'cpu'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {
    "executionInfo": {
     "elapsed": 1201,
     "status": "ok",
     "timestamp": 1610380364611,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "82WSp6khIcua"
   },
   "outputs": [],
   "source": [
    "MODEL = 'bart'\n",
    "MODELS = {}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {
    "executionInfo": {
     "elapsed": 1014,
     "status": "ok",
     "timestamp": 1610380364615,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "ckbpYLpOFwA8"
   },
   "outputs": [],
   "source": [
    "# Output path\n",
    "if 'bart' in MODEL:\n",
    "    data_dir = '/content/drive/My Drive/MAGMA: Summarization/datasets/chunk_chapter/assign_bullets/bart/'\n",
    "    \n",
    "elif 'pegasus' in MODEL:\n",
    "    data_dir = '/content/drive/My Drive/MAGMA: Summarization/datasets/chunk_chapter/assign_bullets/pegasus/'"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "JFd0ppeJyX1o"
   },
   "source": [
    "### **Init**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "executionInfo": {
     "elapsed": 14714,
     "status": "ok",
     "timestamp": 1610379158851,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "yCzod0OizR5U"
   },
   "outputs": [],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "import numpy as np\n",
    "import torch\n",
    "import re\n",
    "import pandas as pd\n",
    "from tqdm import tqdm\n",
    "from textwrap import fill"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "dllOnKR9Os5i"
   },
   "source": [
    "### **Function Definition**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true,
    "id": "U2mpXoSaQiQE"
   },
   "source": [
    "##### Import Model and Tok"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "executionInfo": {
     "elapsed": 14711,
     "status": "ok",
     "timestamp": 1610379158852,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "XhBGMJVFOs5l"
   },
   "outputs": [],
   "source": [
    "def import_model_tok(model_name_or_path):\n",
    "    global MODELS\n",
    "\n",
    "    if model_name_or_path in MODELS.keys():\n",
    "        print('[+] model already present in cache\\n')\n",
    "        return MODELS[model_name_or_path]\n",
    "    print('[*] importing the model\\n')\n",
    "\n",
    "    if 'bart' in MODEL:\n",
    "        from transformers import BartForConditionalGeneration, BartTokenizer\n",
    "\n",
    "        model = BartForConditionalGeneration.from_pretrained(model_name_or_path)\n",
    "        tokenizer = BartTokenizer.from_pretrained(model_name_or_path)\n",
    "    elif 'pegasus' in MODEL:\n",
    "        from transformers import PegasusForConditionalGeneration, PegasusTokenizer\n",
    "\n",
    "        model = PegasusForConditionalGeneration.from_pretrained(model_name_or_path)\n",
    "        tokenizer = PegasusTokenizer.from_pretrained(model_name_or_path)\n",
    "\n",
    "    MODELS[model_name_or_path] = model, tokenizer\n",
    "    print('[+] the model is now present in cache\\n')\n",
    "    return MODELS[model_name_or_path]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true,
    "id": "k0qONrX4Qkkm"
   },
   "source": [
    "##### Nice Print"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "executionInfo": {
     "elapsed": 14709,
     "status": "ok",
     "timestamp": 1610379158854,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "fAB4i6F5O23C"
   },
   "outputs": [],
   "source": [
    "def print_example(idx, text, summ, bull):\n",
    "    print(idx)\n",
    "    print(fill(text, 150))\n",
    "    print()\n",
    "    print('Prediction:')\n",
    "    print(fill(summ, 100))\n",
    "    print()\n",
    "    print('Reference:')\n",
    "    print(fill(bull, 100))\n",
    "    print()\n",
    "    print(''.join(['#']*100))\n",
    "    print()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true,
    "id": "JiYIkI5xN2VA"
   },
   "source": [
    "##### Print Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "executionInfo": {
     "elapsed": 14705,
     "status": "ok",
     "timestamp": 1610379158855,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "dxsXYs1kN5HX"
   },
   "outputs": [],
   "source": [
    "def print_examples(model_name_or_path, df, n_examples=10):\n",
    "    model, tokenizer = import_model_tok(model_name_or_path)\n",
    "    model = model.to(device)\n",
    "    df_examples = df.sample(n_examples, axis='index', random_state=config.SEED)\n",
    "    \n",
    "    for idx, row in df_examples.iterrows():\n",
    "\n",
    "        summ_enc = model.generate(\n",
    "            tokenizer.encode(row.text, return_tensors='pt').to(device),\n",
    "            min_length = config.ONE_BULLET_MIN_LEN,\n",
    "            max_length = config.ONE_BULLET_MAX_LEN,\n",
    "            length_penalty = config.LENGTH_PENALTY,\n",
    "            num_beams = config.NUM_BEAMS,\n",
    "            no_repeat_ngram_size = config.NO_REPEAT_NGRAM_SIZE,\n",
    "            early_stopping = True)[0]\n",
    "        summ = tokenizer.decode(summ_enc, skip_special_tokens=True)\n",
    "\n",
    "        print_example(idx, row.text, summ, row.bullets)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "hidden": true,
    "id": "KV669nVZQnzT"
   },
   "source": [
    "##### Plot Evaluation"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "executionInfo": {
     "elapsed": 14701,
     "status": "ok",
     "timestamp": 1610379158855,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "PrKd0tI7PBi5"
   },
   "outputs": [],
   "source": [
    "def plot_evaluation(model_name_or_path):\n",
    "    df = pd.read_csv(OUTPUT_PATH+model_name_or_path.replace('/', '?')+'.csv').set_index(['book', 'chapter'])\n",
    "\n",
    "    prf = ['precision', 'recall', 'fmeasure']\n",
    "    num_rouge = len(config.ROUGE_TYPES)\n",
    "\n",
    "    from matplotlib.cm import get_cmap\n",
    "    color = get_cmap('tab10')(range(num_rouge))\n",
    "    def set_box_color(b, c):\n",
    "        for k in b.keys():\n",
    "            plt.setp(b[k], color=c)\n",
    "    \n",
    "    xticks = 2*np.array(np.arange(1, num_rouge+1))\n",
    "\n",
    "    fig, ax = plt.subplots(figsize=(10, 6))\n",
    "    box_plt_list = [plt.boxplot(\n",
    "        [df[rouge+'_'+r+'_'+model_name_or_path].tolist() for r in prf],\n",
    "        positions= xticks+var,\n",
    "        sym='+',\n",
    "        widths=0.4,\n",
    "        patch_artist=False,\n",
    "        meanline=True,\n",
    "        showmeans=True)\\\n",
    "        for rouge, var in zip(config.ROUGE_TYPES,\n",
    "            np.linspace(-0.15*num_rouge, 0.15*num_rouge, num_rouge))]\n",
    "\n",
    "    for i, bp in enumerate(box_plt_list):\n",
    "        set_box_color(bp, color[i])\n",
    "        plt.plot([], c=color[i], label=prf[i])\n",
    "    plt.legend()\n",
    "\n",
    "    ax.grid(True, axis='y', alpha=0.7, linestyle='--')\n",
    "    ax.set_title('Evaluation Results', fontsize='xx-large')\n",
    "    ax.set_ylabel('Rouge', fontsize='x-large')\n",
    "    plt.xticks(xticks, config.ROUGE_TYPES, fontsize='x-large')\n",
    "    plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "vb_MdivVauzb"
   },
   "source": [
    "## **Assign Bullets Chunk Chapter**"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 29,
   "metadata": {
    "executionInfo": {
     "elapsed": 14695,
     "status": "ok",
     "timestamp": 1610379158857,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "id": "K98cwOLys0XX"
   },
   "outputs": [],
   "source": [
    "df_train = pd.read_csv(data_dir + 'train.csv').set_index(['book', 'chapter'])\n",
    "df_val = pd.read_csv(data_dir + 'val.csv').set_index(['book', 'chapter'])\n",
    "df_test = pd.read_csv(data_dir + 'test.csv').set_index(['book', 'chapter'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "dpNmnjXn3u2U"
   },
   "source": [
    "### **Print and Summarization**"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "WIiEnpvbMkJa"
   },
   "source": [
    "##### Print Train Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 30,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 0,
     "referenced_widgets": [
      "6031334cc0ca4091a8ff6fb7637d3229",
      "05874631cf9342bb92a95ed2e24ff2c7",
      "faaac5a54b4d4ea0bb61083f9e035cb6",
      "302c0bd9016a4e1fa805350c13c64c59",
      "b2332832806b434c92b67aa4fbb169dd"
     ]
    },
    "executionInfo": {
     "elapsed": 107899,
     "status": "ok",
     "timestamp": 1610379252066,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "wgZKNh2f3u2l",
    "outputId": "045e626c-dc34-4c01-b0d6-f885aa9d948c"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[*] importing the model\n",
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6031334cc0ca4091a8ff6fb7637d3229",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=1621.0, style=ProgressStyle(description…"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "05874631cf9342bb92a95ed2e24ff2c7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=1222317369.0, style=ProgressStyle(descr…"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "faaac5a54b4d4ea0bb61083f9e035cb6",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=898822.0, style=ProgressStyle(descripti…"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "302c0bd9016a4e1fa805350c13c64c59",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=456318.0, style=ProgressStyle(descripti…"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b2332832806b434c92b67aa4fbb169dd",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "HBox(children=(FloatProgress(value=0.0, description='Downloading', max=26.0, style=ProgressStyle(description_w…"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "[+] the model is now present in cache\n",
      "\n",
      "(9781912776696, 'hh-5')\n",
      "Time to-event endpoints . Many endpoints in oncology are time-to-event endpoints, id est the time until a specified event of interest occurs, such as\n",
      "death or the occurrence of disease . Typical examples are . overall survival (OS) . progression-free survival (PFS) . disease-free survival (DFS) .\n",
      "duration of response . Often these endpoints are measured from the time the participants in a study are randomized into treatment groups . This is the\n",
      "case for OS, PFS and DFS, but duration of response is measured from the time point at which partial or complete response is achieved to disease\n",
      "progression . Time-to-event analyses include information from both censored and uncensored observations (see below) . Censoring is a common feature of\n",
      "all time-to-event endpoints . A subject's time to event is said to be censored if the event of interest (death, disease progression etc . has not\n",
      "occurred in that patient by the end of the follow-up period . A censored observation can also occur when information on a subject is known for a\n",
      "limited duration only (exempli gratia if a person drops out of a study before the end and is lost to follow-up) . In a study with a fixed 24-month\n",
      "follow-up, a subject who is still alive at month 24 will provide a censored value for OS . The OS for such a subject is considered to be at least as\n",
      "long as the duration of the study . At the time of an interim analysis, some subjects may not have been in the study for very long . These subjects\n",
      "will provide censored values if the event of interest has not occurred during the limited follow-up . Kaplan-Meier curves . Kaplan-Meier curves\n",
      "provide a way of plotting the distribution of a time-to-event endpoint . In Figure 2.1 the dashed line shows that at 24 months' follow-up the\n",
      "estimated survival probability is 54% . Kaplan-Meier survival curves are often used to compare the data between two groups of subjects . Figure 2.2\n",
      "shows Kaplan-Meier curves for OS in a randomized study of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast\n",
      "cancer treated either with or without trastuzumab . The Kaplan-Meier curve steps down at time points at which deaths occur, while censored\n",
      "observations are denoted by notches on the curve . In this study, the follow-up period ranged from 3 months to 74 months . The Kaplan-Meier curve\n",
      "plots the probability of being event free over time, with these probabilities being estimated from the data in the study . Note that the curve for\n",
      "patients who received trastuzumab is consistently above the curve for those who did not receive trastuzumab, indicating a higher survival probability\n",
      "in that group . For the rest of this chapter, for simplicity, let us assume that the event of interest is death . Median overall survival . The\n",
      "Kaplan-Meier curves can be used to obtain median survival times (Figure 2.3) . The median survival time is the time point at which 50% of patients are\n",
      "estimated to be alive, and this can be found by drawing a horizontal line at the 50% line on the y -axis .\n",
      "\n",
      "Prediction:\n",
      " Many endpoints in oncology are time-to-event endpoints, id est the time until a specified event of\n",
      "interest occurs. Typical examples are overall survival (OS) progression-free survival (PFS) and\n",
      "disease-free survival (DFS) Time-to-event analyses include information from both censored and\n",
      "uncensored observations (see below)\n",
      "\n",
      "Reference:\n",
      "Kaplan-Meier curves plot the probability of being event free over time. The curves from different\n",
      "treatment groups can be plotted against each other to show the differences in outcome.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541062, 'ch_9')\n",
      "Management - traditional measures . The acute and chronic consequences of rheumatoid arthritis (RA) result from persistent, misdirected and\n",
      "inadequately controlled inflammation that causes tissue destruction and loss of function . Consequently, management strategies for RA have become\n",
      "highly refined over the past 10 years . The concept of long-term therapy with non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids while\n",
      "awaiting a natural remission is no longer acceptable . Rheumatologists today initiate disease-modifying antirheumatic drug (DMARD) therapy as soon as\n",
      "the diagnosis of RA is secure . Subsequently, therapy is aggressively adjusted until a state of low disease activity or remission is achieved . For\n",
      "this reason, it is critical that patients are referred for specialist assessment as soon as the diagnosis of RA is suspected, and even before the\n",
      "results of investigations are available . Early control of inflammation and the disease process is essential to minimize irreversible joint damage and\n",
      "functional disability . Most patients will commence therapy with methotrexate, either alone or ideally in combination with other DMARDs . With\n",
      "aggressive DMARD therapy a proportion of patients will achieve disease remission, and those who do not can now receive biological therapies (see\n",
      "Chapter 9) within a few months of diagnosis . The patient must be fully educated about treatment options and expectations from the outset, and\n",
      "decisions regarding drug therapy must be mutually agreed . Furthermore, the rheumatologist must serve as an advocate for the patient with regard to\n",
      "treatment and drug monitoring programs . In the USA this is particularly important, in light of potential restrictions due to changes in the\n",
      "healthcare reimbursement system and managed care . Economic considerations have also become important in the UK, although recent guidelines from the\n",
      "National Institute for Health and Clinical Excellence (NICE) have reduced some previous restrictions on the prescribing of biologics (see Chapter 9) .\n",
      "Patients treated by rheumatologists have a slower rate of disease progression, and less joint damage and disability, than those not receiving care\n",
      "from an arthritis specialist . The expertise of the rheumatologist is in advising drug regimens, referring to rehabilitation specialists, and\n",
      "recognizing the importance and timing of orthopedic consultation and procedures . Non-pharmacological approaches . Reduction of joint stress can be\n",
      "accomplished by local rest of an inflamed joint . Weight reduction, splinting, use of walking aids and specially designed utensils can all\n",
      "significantly reduce stress on joints . During significant disease flares, vigorous activity should be avoided, although full range of motion of\n",
      "joints should be maintained by a graded exercise program to prevent contractures and muscular atrophy . The role of physical and occupational therapy,\n",
      "podiatry, nursing educational programs and vocational rehabilitation cannot be overemphasized . Rest, splinting of involved joints, adaptive\n",
      "equipment, appropriate exercise programs, orthotics, foot care and bespoke shoes, and nutritional and physiological support are all essential\n",
      "ingredients of a successful treatment regimen . Pharmacological approaches - overview . The traditional 'pyramid' approach to the treatment of RA was\n",
      "to begin with symptomatic treatment of inflammation using NSAIDs in addition to rest and corticosteroid injections . If the disease did not\n",
      "significantly improve with these simple treatments, then more potent DMARDs were added . It is now clear, however, that effective therapy early in the\n",
      "course of RA results in a long-term reduction in joint damage compared to delayed therapy, the so-called window of opportunity . This has led to the\n",
      "general principle that inflammation should be controlled as completely and as soon as possible by the early and aggressive introduction of DMARDs .\n",
      "The currently approved non-biological drugs for treating RA are listed in Table 8.1 . Most of these require monitoring for the prompt detection of\n",
      "potential adverse effects, although the precise monitoring recommendations vary from center to center . The British Society for Rheumatology, the\n",
      "European League Against Rheumatism and the American College of Rheumatology have each developed guidelines for the use and monitoring of RA therapies\n",
      ". Non-steroidal anti-inflammatory drugs . NSAIDs remain one of the most frequently prescribed class of drugs in the treatment of patients with RA, at\n",
      "least early in the disease process .\n",
      "\n",
      "Prediction:\n",
      " Rheumatologists today initiate disease-modifying antirheumatic drug (DMARD) therapy as soon as the\n",
      "diagnosis of RA is secure. Patients treated by rheumatologists have a slower rate of disease\n",
      "progression, and less joint damage and disability, than those not receiving care from an arthritis\n",
      "specialist.\n",
      "\n",
      "Reference:\n",
      "Consequently, the patient with RA is optimally managed from disease onset by a rheumatologist and\n",
      "their multidisciplinary team.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797495, 'chp8')\n",
      "Persistent postsurgical pain . Persistent postsurgical pain . It is now clear from numerous studies that persistent postsurgical pain (PPSP) is one of\n",
      "the major causes of persistent (chronic) pain . Limited data also indicate that a significant percentage of patients continue to have pain following\n",
      "trauma, particularly trauma to multiple body areas or traumatic amputation . Although there is evidence that nerve damage plays a key role, there are\n",
      "other factors that probably determine which patients with nerve damage progress from acute to persistent pain as, in many operations (exempli gratia\n",
      "amputation), all patients have nerve damage but only a percentage (10-50%) progress to chronic pain (Table 8.1) . The only reliable data currently\n",
      "available derive from postsurgery patients and thus this discussion will be limited to these patients . It is possible, but not studied, that similar\n",
      "factors may occur in post-trauma patients (many of whom also undergo surgery) . A major review of this subject by Kehlet et al . was published in 2006\n",
      ". The factors in Table 8.2 are associated with increased risk of PPSP, but no comprehensive study has been carried out to evaluate their relative\n",
      "importance . Although evidence of genetic factors is not available for PPSP, Tegeder et al . (2006) have identified a genetic influence on the\n",
      "development of chronic pain following an acute episode of sciatica . More attention is now being focused on the influence of other patient factors,\n",
      "such as catastrophizing and depression, which influence perioperative and postoperative pain and analgesic use . Preoperative pain intensity has been\n",
      "correlated with postoperative pain intensity in a prospective study of 346 patients undergoing abdominal surgery . The intensity of postoperative pain\n",
      "has been linked to the prevalence of chronic pain . Thus, improved acute pain control pre- and postoperatively may help to prevent PPSP . There is\n",
      "also evidence that intra- and postoperative use of epidural or regional neural blockade may be helpful . Surgical technique may play a role, as 'nerve\n",
      "preservation' techniques appear to lower the incidence of PPSP - although no studies have prospectively addressed this area . The introduction of\n",
      "video-assisted thoracic surgery made no difference to the incidence of post-thoracotomy PPSP at 1 year after surgery . This serves to illustrate how\n",
      "difficult it is to avoid trauma to nerves at various surgical sites, and that factors other than nerve injury are involved in PPSP . In the early\n",
      "stages of PPSP surgeons tend to suspect a surgical complication of some sort (exempli gratia a wound hematoma, chronic infection, incomplete repair of\n",
      "an inguinal hernia) . Initially, a reasonable attempt should be made to rule out such diagnoses . However, in the majority of cases no remediable\n",
      "surgical complication will be found . Recognition that the patient has chronic pain, and that the pathophysiology is in the central nervous system,\n",
      "not in the peripheral tissues, is now needed . Patient education . As the majority of PPSP is caused by nerve damage, the treatment options are\n",
      "similar to those for other neuropathic pain syndromes . Pharmacotherapy alone will rarely be sufficient .\n",
      "\n",
      "Prediction:\n",
      " Persistent postsurgical pain (PPSP) is one of the major causes of persistent (chronic) pain. A\n",
      "significant percentage of patients continue to have pain following trauma, particularly trauma to\n",
      "multiple body areas or traumatic amputation.\n",
      "\n",
      "Reference:\n",
      "Effective acute pain control may be preventive for PPSP - for example, intra- and postoperative use\n",
      "of epidural analgesia can prevent PPSP following some operations.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541666, 'ch_12')\n",
      "In the last few years, continuation of subcutaneous long-acting basal analogs has become widespread practice to provide background insulin when the\n",
      "insulin infusion is stopped and prevent rebound hyperglycemia . Insulin therapy and correction of acidosis decreases potassium levels, and most\n",
      "patients will require intravenous potassium supplementation to prevent hypokalemia and replace total body potassium deficit . The use of bicarbonate\n",
      "to correct acidosis is not recommended as studies have failed to show any benefit from bicarbonate administration, which may actually be harmful .\n",
      "Once ketoacidosis is resolved, hyperglycemia has been corrected and the patient has improved clinically and is eating and drinking, subcutaneous\n",
      "insulin administration can resume . The prognosis of DKA is usually determined by the precipitating cause . The overall mortality is 3-4% . Cerebral\n",
      "edema is a rare life-threatening complication usually encountered in children with DKA (around 1% of episodes) . It carries a mortality of 40-90% and\n",
      "manifests as a decreasing level of consciousness, with headache, seizures, papilledema, bradycardia and respiratory arrest . Treatment is with\n",
      "intravenous mannitol . Mechanical ventilation may help to reduce swelling of the brain . In the UK, 70-80% of diabetes-related deaths in children\n",
      "under 12 years of age are caused by cerebral edema . When a patient presents with DKA, every effort should be made to identify the cause where\n",
      "possible in order to establish strategies to prevent a recurrence . Hyperosmolar hyperglycemic state . Hyperosmolar hyperglycemic state (HHS) is one\n",
      "of the two serious metabolic derangements in diabetes that may be life-threatening . It is less common than DKA, but carries a higher mortality rate\n",
      "(10-20%) . Other terms used to describe the condition include diabetic hyperosmolar non-ketoacidotic coma, hyperosmolar hyperglycemic non-ketotic coma\n",
      "and hyperosmolar non-ketotic state . HHS is characterized by severe hyperglycemia, dehydration and hyperosmolarity in the absence of\n",
      "ketonemia/ketonuria and acidosis (Table 11.4) . HHS usually occurs in middle-aged or elderly patients with type 2 diabetes (often undiagnosed) . The\n",
      "absence of ketoacidosis in HHS is not fully explained but may be because such individuals have insulin levels low enough to cause hyperglycemia but\n",
      "adequate to inhibit lipolysis and ketogenesis because of the differential effect of insulin on lipolysis and glucose uptake . HHS occurs in patients\n",
      "with type 2 diabetes in the presence of a concomitant illness that leads to reduced fluid intake . Infection (commonly urinary tract infection and\n",
      "pneumonia) is the preceding illness in 30-60% of cases . Other relatively frequent causes include myocardial infarction, stroke and concomitant drug\n",
      "use such as thiazide diuretics or corticosteroids . Clinical presentation . Typically, patients have symptoms of diabetes and weakness . A wide\n",
      "variety of focal neurological abnormalities (exempli gratia focal or generalized seizures, hemiparesis) or global neurological abnormalities (exempli\n",
      "gratia drowsiness, delirium, coma) may be present . Patients are clinically severely volume-depleted and often there are signs of infection when this\n",
      "is the precipitating cause . Treatment of HHS by fluid, electrolyte and insulin replacement is as for DKA (fluid deficits may be large [exempli gratia\n",
      "10 L or more]) . Attention should be focused on the underlying cause when identifiable . Thromboembolic events occur in HHS and treatment with low-\n",
      "molecular-weight heparin is recommended for those with established thromboembolic disease, immobility or risk factors for venous thrombosis .\n",
      "\n",
      "Prediction:\n",
      " Hyperosmolar hyperglycemic state (HHS) is one of the two serious metabolic derangements in diabetes\n",
      "that may be life-threatening. It is less common than DKA, but carries a higher mortality rate\n",
      "(10-20%) It is characterized by severe hyperglycemia, dehydration and hyperosmolarity in the absence\n",
      "of ketonemia/ketonuria and acidosis.\n",
      "\n",
      "Reference:\n",
      "The overall mortality of DKA is 3-4%.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797495, 'chp1')\n",
      "After tissue or nerve damage, peripheral nociceptors become sensitized to noxious stimuli owing to the formation and accumulation of algogenic and\n",
      "inflammatory mediators in the periphery, such as prostanoids, interleukins, bradykinin and histamine . Peripheral sensitization and heightened\n",
      "afferent activity in pain fibers elicit functional, chemical and anatomic reorganization in spinal cord neurons . These changes lead to long-term\n",
      "central potentiation, a form of pain memory characterized by progressively enhanced and prolonged spinal neuronal responses to afferent impulses .\n",
      "This spatially and temporally exaggerated processing of persistent nociceptive information translates clinically into increased experience of pain -\n",
      "not only response to noxious stimulation in the injured tissue (primary hyperalgesia), but also response in the surrounding uninjured tissue\n",
      "(secondary hyperalgesia), with repetitive stimulation producing progressively greater neuronal responses . Central potentiation is due to the release\n",
      "by spinal afferent nociceptive neurons of excitatory mediators such as substance P and glutamate that bind to neurokinin-1 (NK1) and N -methyl D\n",
      "-aspartate (NMDA) receptors, respectively, in the dorsal horn . Concurrent activation of these receptors allows a massive influx of calcium into\n",
      "second-order neurons, the cell bodies of which lie within the dorsal horn of the spinal cord . Consequently, calcium-dependent intracellular enzymes\n",
      "such as protein kinase C (PKC) are activated, catalyzing the production of nitric oxide (NO) and prostaglandins . These protein kinases also activate\n",
      "other proteins such as ion channels and enzymes (Figure 1.3) . Pain also triggers processes that dampen the perception of nociceptive stimuli .\n",
      "Nociceptive afferent traffic ascends to the midbrain and brainstem, where it activates descending pathways that inhibit spinal pain transmission (see\n",
      "Figure 1.2) . These descending inhibitory systems are stimulated by endogenous opioids, as well as monoamines such as norepinephrine (noradrenaline)\n",
      "and serotonin . They inhibit spinal nociceptive transmission through the local release of inhibitory transmitters such as gamma-aminobutyric acid\n",
      "(GABA), glycine, adenosine and endogenous opioids at the spinal level . Analgesics such as opioids, tricyclic antidepressants and serotonin-\n",
      "norepinephrine-reuptake inhibitors (SNRIs), in addition to their other mechanisms of action, activate these inhibitory systems . Furthermore, pain\n",
      "elicits a stress hormone response that includes the systemic secretion of endogenous opioids from the anterior pituitary and the adrenal medulla .\n",
      "Pain is more than the nociceptive cascade described above . Pain is 'an unpleasant sensory and emotional experience associated with actual or\n",
      "potential tissue damage, or described in terms of such damage' (International Association for the Study of Pain [IASP]) . Because it is an experience,\n",
      "pain itself cannot be measured directly . Pain, like consciousness itself, is constructed by complex brain processes that are strongly affected by a\n",
      "person's attitudes, beliefs, personality and interpretation of the significance of nociceptive stimuli . Central to the understanding of clinical pain\n",
      "is the concept that pain may be present without an obvious peripheral source or cause . Mechanisms of neuropathic pain . Neuropathic pain is initiated\n",
      "or caused by a primary lesion of the PNS or CNS . Patients often complain not only of spontaneous pain, but also of pain from stimuli that are not\n",
      "normally painful (allodynia) . For example, a light touch may be described as painful . Important types of neuropathic pain and their probable causes\n",
      "are shown in Table 1.2, and are discussed in more detail in subsequent chapters . Several neuropathic pain syndromes share overlapping pathogenic\n",
      "mechanisms . Those pain syndromes that have unique pathogenic mechanisms are discussed in the relevant chapters . Among other classifications,\n",
      "pathogenic mechanisms can be considered as either peripheral or central . Peripheral nerve injury produces axonal membrane hyper-excitability that\n",
      "leads to spontaneous generation of ectopic impulses . In addition, changes in the chemical environment surrounding the damaged axon trigger ectopic\n",
      "nerve action potentials, which lead to further impulses (Figure 1.4) .\n",
      "\n",
      "Prediction:\n",
      " After tissue or nerve damage, peripheral nociceptors become sensitized to noxious stimuli owing to\n",
      "the formation and accumulation of algogenic and inflammatory mediators in the periphery. Peripheral\n",
      "sensitization and heightened afferent activity in pain fibers elicit functional, chemical and\n",
      "anatomic reorganization in spinal cord neurons. These changes lead to long-term central\n",
      "potentiation, a form of pain memory characterized by progressively enhanced and prolonged spinal\n",
      "neuronal responses to afferent impulses. Pain also triggers processes that dampen the perception of\n",
      "nociceptive stimuli. Pain is more than the nociceptive cascade described above. Pain is 'an\n",
      "unpleasant sensory and emotional experience associated with actual or potential tissue damage'\n",
      "\n",
      "Reference:\n",
      "Nociceptive input activates descending pathways that inhibit spinal noxious transmission. These\n",
      "descending pathways are potential targets for analgesic drugs.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797662, 'ch03')\n",
      "Recurrent urinary tract infections . Recurrent UTI is sometimes due to the presence of a bladder tumor . A single UTI in a man, or two or more in a\n",
      "woman, should be investigated; however, the likelihood of a malignant etiology is very low in patients under 50 years of age . Symptoms of local or\n",
      "distant spread . Patients sometimes present with systemic symptoms due to advanced carcinoma of the bladder . Loin pain can be caused by ureteric\n",
      "obstruction due to an invasive bladder tumor (Figure 3.1) . The pain is usually a dull ache in the costophrenic angle, and may or may not coincide\n",
      "with other symptoms such as hematuria . Occasionally, infection occurs in an obstructed system, giving rise to severe symptoms of pyelonephritis .\n",
      "Coughing, dyspnea or chest pain may be due to pulmonary metastases (Figure 3.2); the cough is usually non-productive . Pleuritic chest pain may also\n",
      "be present . Anorexia, nausea, weight loss and malaise may result from renal failure due to bilateral ureteric obstruction, or from the systemic\n",
      "effects of the tumor itself . Bone pain or pathological fractures may result from skeletal metastases (Figure 3.3); the pain is unrelieved by rest and\n",
      "can be severe . Anemia and hypercalcemia may occur as metabolic complications of advanced disease; leukocytosis is occasionally associated with the\n",
      "elaboration of colony-stimulating factors by the tumor . Headache or disordered thought processes are uncommon as a presenting feature but may\n",
      "indicate underlying brain metastases or carcinomatous meningitis . Delay in diagnosis . Although it is difficult to prove that delay in diagnosis\n",
      "affects prognosis, screening for asymptomatic microscopic hematuria is associated with a shift towards more favorable tumor characteristics of lower\n",
      "stage and grade at diagnosis, and better survival . Delays may occur for a variety of reasons . Presentation by the patient may be delayed because of\n",
      "anxiety about the cause of the symptoms, fear of primary care physicians or hospitals or ignorance of the significance of symptoms . Referral by the\n",
      "primary care physician to a specialist may be delayed because of ignorance of the significance of the symptoms, or limited access to specialist\n",
      "healthcare (waiting times for clinic appointments) . Diagnosis by the specialist may be delayed because of waiting times for investigations, follow-up\n",
      "clinic appointments for results, or cystoscopy . Taken together, these factors mean that the average time from the first symptom to treatment of the\n",
      "bladder tumor varies from a few weeks to more than a year across studies . In an attempt to streamline the diagnosis and treatment of patients with\n",
      "symptoms suggestive of bladder cancer, many hospitals now offer a hematuria clinic at which patients can be seen within a week of referral . The\n",
      "service should be able to perform urine cytology and dipstick analysis for blood and leukocytes, CTU or renal ultrasonography and plain radiography of\n",
      "the urinary tract, and flexible cystoscopy, all on the same day . This allows a diagnosis to be made and treatment planned expeditiously .\n",
      "\n",
      "Prediction:\n",
      " Patients sometimes present with systemic symptoms due to advanced carcinoma of the bladder. Loin\n",
      "pain can be caused by ureteric obstruction due to an invasive bladder tumor. Coughing, dyspnea or\n",
      "chest pain may be due to pulmonary metastases. Anemia and hypercalcemia may occur as metabolic\n",
      "complications of advanced disease.\n",
      "\n",
      "Reference:\n",
      "Delay in treatment adversely affects prognosis.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797310, 'chp2')\n",
      "Diagnosis and pathological classification . The most common symptoms of advanced intrathoracic disease are cough, hemoptysis, dyspnea, chest pain,\n",
      "bronchial obstruction and dysphagia . These symptoms usually trigger a chest X-ray (CXR) . Some lung cancers are identified by an abnormality found on\n",
      "imaging that is carried out for reasons other than chest symptoms (exempli gratia for employment reasons or before elective surgery) . Initial\n",
      "evaluation of a patient after imaging should involve tissue biopsy by bronchoscopy, endobronchial ultrasound, or guided ultrasonography or CT . This\n",
      "information, together with radiological staging and a multidisciplinary meeting discussion usually results in a treatment plan . This plan must then\n",
      "be considered in terms of the patient's comorbidities (cardiac and respiratory function) and individual wishes . Every patient with suspected lung\n",
      "cancer should undergo a thorough history and physical examination, which, together with laboratory testing can assess comorbid conditions and the\n",
      "likelihood of metastases . CT, and in some cases positron emission tomography (PET), provides a non-invasive assessment of tumor size (T), mediastinal\n",
      "node enlargement (N) and potential metastases (M) (see Staging, Chapter 3) . Small biopsies and cytology specimens . About 70% of patients present\n",
      "with advanced stage lung cancer . Diagnosis is usually made from small biopsy and cytology specimens . Historically, pathologists only needed to\n",
      "distinguish between small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), but in recent years therapeutic and genetic advances have\n",
      "driven the need for larger quantities of tissue for histological subclassification, immunohistochemistry and molecular and immune pathology . The 2015\n",
      "World Health Organization Classification of Tumors of the Lung, Pleura, Thymus and Heart includes a new classification for small biopsies and cytology\n",
      "similar to that proposed in the 2011 Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification .\n",
      "Well-differentiated tumors with adenocarcinoma morphology (acinar, papillary, lepidic, micropapillary) or squamous cell carcinoma (unequivocal\n",
      "keratinization and well-formed classical bridges) on routine light microscopy can be diagnosed as adenocarcinoma or squamous cell carcinoma,\n",
      "respectively, without immunohistochemistry . Poorly differentiated tumors should undergo limited immuno-histochemistry . A single adenocarcinoma\n",
      "marker (exempli gratia thyroid transcription factor 1 [TTF1] or Napsin-A) or squamous cell carcinoma marker (exempli gratia p40, cytokeratin 5/6 or\n",
      "p63) can be used to classify most tumors . Carcinomas lacking clear differentiation by morphology and immunohistochemistry are classified as 'NSCLC,\n",
      "not otherwise specified (NOS)' . NOS carcinomas that stain with adenocarcinoma markers are classified as 'NSCLC, favor adenocarcinoma'; tumors that\n",
      "stain with squamous markers are classified as 'NSCLC, favor squamous cell carcinoma' . In this way, a diagnosis of NSCLC-NOS can be avoided in up to\n",
      "90% of cases . Molecular testing for tumor gene (somatic) mutations . The discovery of specific gene mutations in NSCLC (Table 2.1) has led to the\n",
      "development of targeted therapies . In particular, the presence of epidermal growth factor receptor (EGFR) gene mutations, found primarily in\n",
      "adenocarcinomas, is predictive of responsiveness to EGFR tyrosine kinase inhibitors . Furthermore, adenocarcinomas with ALK - MET rearrangements are\n",
      "responsive to crizotinib, and patients with adenocarcinoma or NSCLC-NOS are more responsive to pemetrexed than are those with squamous cell carcinoma\n",
      ". In the initial randomized phase 2 study of bevacizumab and chemotherapy in advanced NSCLC, bevacizumab was associated with life-threatening\n",
      "hemorrhage in patients with squamous cell carcinoma; therefore, it is contraindicated in patients with this NSCLC histology .\n",
      "\n",
      "Prediction:\n",
      " The most common symptoms of advanced intrathoracic disease are cough, hemoptysis, dyspnea, chest\n",
      "pain, bronchial obstruction and dysphagia. About 70% of patients present with advanced stage lung\n",
      "cancer. Diagnosis is usually made from small biopsies and cytology specimens. Diagnosis of NSCLC-NOS\n",
      "can be avoided in up to 90% of cases.\n",
      "\n",
      "Reference:\n",
      "Classification of NSCLC further into specific pathological subtypes (exempli gratia adenocarcinoma\n",
      "versus squamous cell carcinoma) will determine eligibility for certain types of molecular testing\n",
      "and aid therapeutic decisions based on the specific histological and genetic characteristics of the\n",
      "tumor.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797587, 'chp03')\n",
      "Osteoarthritis (OA) is the most common joint disorder and represents a major cause of pain and disability for the individual, as well as resulting in\n",
      "enormous health expenditure in Western countries . In the USA, an estimated 30 million people are affected by the disorder, while in the UK some 8.75\n",
      "million people aged 45 years or older sought treatment for OA between 2004 and 2010 . OA has been ranked as the tenth leading contributor to years\n",
      "lived with disability (YLD) worldwide, accounting for 2.4% of all YLDs . It was the third most rapidly rising condition associated with disability,\n",
      "with YLDs increasing by 75% between 1990 and 2013, behind diabetes (135%) and dementia (84%) . The joints most commonly affected are the . hands: base\n",
      "of thumb, distal and proximal interphalangeal joints . spine: cervical and lumbosacral . first metatarsophalangeal joint . OA is not an acquired\n",
      "disease in the traditional medical model, and definitions have not always been clear . OA is a syndrome of joint pain and stiffness with associated\n",
      "functional problems, which can have a substantial effect on quality of life . In terms of structural abnormalities, OA encompasses a number of\n",
      "problems that result in common pathological and radiological features . The OA disease process in synovial joints is classically characterized in its\n",
      "later stages by focal cartilage degradation, involvement of the subchondral bone and synovium, and the formation of marginal osteophytes; in reality,\n",
      "all components of the joint are affected (see Chapter 2) . Importantly, periarticular tissue, especially muscle, is often affected as well . It is\n",
      "difficult to estimate the true global prevalence of OA as many studies consider only hip and knee OA . The 2013 Global Burden of Disease (GBD) study\n",
      "estimated that 242 million people worldwide were affected by symptomatic OA of the hip and/or knee and that the global prevalence of hip and knee OA\n",
      "is approaching 5% . Estimates of incidence and prevalence also vary according to the definition of OA used; for example, symptomatic versus\n",
      "radiographic criteria . Even when radiographic definitions are used, different radiographic features may be emphasized (exempli gratia osteophytes vs\n",
      "joint-space narrowing) . It is interesting to note that the correlation between pain and radiographic OA features is not as strong as expected, for\n",
      "reasons discussed in Chapter 4 (see page 50) . Radiographic OA is more common than symptomatic OA, and detection rates in a given joint may increase\n",
      "when more radiographic views are obtained . Studies on the distribution of radiographic OA have suggested that right-sided hand and knee OA is more\n",
      "common than left-sided disease (consistent with a biomechanical cause) . Even within a specific joint, the distribution of osteophytes or joint-space\n",
      "narrowing differs in prevalence, as well as by sex and ethnicity, again reflecting biomechanical and genetic factors (Table 3.1) . In the hand, the\n",
      "most common combinations of joints affected by radiographic OA are the distal and proximal interphalangeal joints with or without the carpometacarpal\n",
      "joint . However, because ultrasound can visualize the joint in three dimensions, studies using ultrasound have suggested metacarpophalangeal joint OA\n",
      "to be more common than radiographic studies suggest . Effect of age . Individual joints demonstrate a striking age-related rise in the prevalence of\n",
      "radiographic OA . About one-third of all adults have radiographic OA of the hands, with two-thirds over 75 years of age exhibiting OA of the distal\n",
      "interphalangeal joints . Radiographic OA of the knees has also been found in about a third of adults over 60 years of age (Table 3.2) . Effect of sex\n",
      ". The prevalence of radiographic OA (particularly of the hand and knee) is higher in women than men, especially in individuals over 50 years of age .\n",
      "Effect of ethnicity . The prevalence of large joint radiographic OA in joints other than the hand is higher in African-Americans than in American\n",
      "whites . Ethnic differences have also been demonstrated in (mainland) Chinese people, with the prevalence of hip and hand OA being substantially lower\n",
      "in men and women from Beijing than in US cohorts assessed using the same methods .\n",
      "\n",
      "Prediction:\n",
      " Osteoarthritis (OA) is the most common joint disorder and represents a major cause of pain and\n",
      "disability. In the USA, an estimated 30 million people are affected by the disorder, while in the UK\n",
      "some 8.75 million people aged 45 years or older sought treatment for OA between 2004 and 2010. OA\n",
      "has been ranked as the tenth leading contributor to years lived with disability.\n",
      "\n",
      "Reference:\n",
      "Although radiographic OA is common, it is not always symptomatic.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541963, 'chapter10')\n",
      "Hepatocellular carcinoma . Epidemiology and pathogenesis . Hepatocellular carcinoma (hepatoma, HCC) is a malignancy of hepatocytes . HCC is a common\n",
      "cause of mortality in the developing world . Although currently less common in the developed world, the incidence is expected to rise as patients with\n",
      "cirrhosis due to chronic hepatitis C age . Marked geographic variation in incidence is largely due to variation in the risk factors that predispose an\n",
      "individual to the tumor (Table 10.1) . Most cases of HCC occur in liver that is already cirrhotic . Thus, patients with advanced viral hepatitis,\n",
      "hemochromatosis or alcoholic liver disease are at risk . Hepatitis B presents a unique risk, as there is evidence that a tumor may develop in the\n",
      "absence of cirrhosis - presumably via direct integration of viral DNA into the host genome . Clinical presentation . HCC is difficult to diagnose\n",
      "until there is widespread involvement of the liver . Symptoms and changes on physical examination are not specific, and are usually attributed to the\n",
      "underlying liver disorder (Table 10.2) . The standard liver biochemical markers are not particularly helpful, although sudden elevations in bilirubin\n",
      "or alkaline phosphatase may suggest obstruction of the biliary tree by a tumor . In the absence of specific clinical findings, most hepatologists\n",
      "suspect HCC when there is a change in the expected clinical course of a patient with otherwise stable liver disease . Paraneoplastic syndromes related\n",
      "to HCC may also give clues to the diagnosis (Table 10.3) . Because of the non-specific clinical presentation, the diagnosis of HCC is typically made\n",
      "using serum tumor markers, imaging studies and, at times, liver biopsy . Alpha fetoprotein . Immature (fetal) liver cells synthesize alpha fetoprotein\n",
      "(AFP) . Malignant hepatocytes resemble immature hepatocytes, and AFP is an important marker for HCC . A sudden rise in serum AFP or absolute levels\n",
      "greater than 500 ng/mL are highly suggestive of HCC . Lower levels can be seen with any liver disease that provokes hepatocyte regeneration (ongoing\n",
      "hepatitis, cirrhosis) . AFP is also produced during pregnancy and by some germ-cell tumors . Unfortunately, not all HCCs produce AFP; 30-40% of\n",
      "patients with HCC have normal AFP levels, which considerably limits the usefulness of AFP for screening . Imaging studies are particularly useful when\n",
      "confirming a diagnosis of HCC . Ultrasonography is inexpensive, safe and convenient . Although widely used, its sensitivity is only about 50% . CT,\n",
      "especially when used with rapid scanning techniques, helps to identify and stage the tumor . It has better sensitivity than ultrasonography, making it\n",
      "particularly useful for detecting small tumors . MRI, angiography and positron emission tomography may each provide additional information . Because\n",
      "of rapidly changing imaging technology and variability in local availability, consultation with a radiologist is strongly recommended . Many\n",
      "hepatologists believe that suspected HCC lesions (suspected on the basis of imaging characteristics, growth patterns and elevated AFP levels) should\n",
      "not be biopsied for fear that the biopsy may spread the tumor . However, clinicians may be faced with presentations that are less clear, and needle\n",
      "biopsy of the liver is required to confirm the diagnosis . Available data do not strongly support the efficacy of screening for HCC .\n",
      "\n",
      "Prediction:\n",
      " Hepatocellular carcinoma (hepatoma, HCC) is a malignancy of hepatocytes. HCC is difficult to\n",
      "diagnose until there is widespread involvement of the liver. Most cases of HCC occur in liver that\n",
      "is already cirrhotic. HCC is a common cause of mortality in the developing world.\n",
      "\n",
      "Reference:\n",
      "Hepatocellular carcinoma often has few specific symptoms or signs.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797273, 'chp6')\n",
      "The concept of self-renewing multipotent stem cells (id est cells that can differentiate into any cell type) as the basis for tissue repair in the\n",
      "nervous system, which has a physiologically limited regenerative capacity in adults, is extremely attractive . Mesenchymal tissue can be harvested\n",
      "from bone marrow, placental or adipose tissue, and multipotent mesenchymal stem cells expanded and purified in vitro . From only a few stem cells,\n",
      "billions/trillions of self-regenerating stem cells can be grown using specific nutrients (growth factors) and then readministered to the patient\n",
      "(intravenously or intrathecally) without the need for toxic conditioning regimens . Evidence from preclinical studies in experimental autoimmune\n",
      "encephalomyelitis (EAE) models supports both an immunomodulatory and neuroprotective role for mesenchymal stem cells . Experimental (Phase I/II)\n",
      "studies have demonstrated the feasibility of this approach in humans, with no serious adverse reactions reported to date . Although there have been\n",
      "only a few dozen patients in open-label studies so far, early data suggest that these cells may have an ameliorating effect on inflammation in\n",
      "patients with MS . The capacity of these cells to differentiate into physiologically functional neural tissue (remyelination/regeneration) is yet to\n",
      "be determined . Anti-LINGO-1 . Promoting repair has been an unexplored sphere of MS therapy . Recently, in animal models of demyelination, LINGO\n",
      "antagonists have been shown to promote oligodendrocyte differentiation and myelination in vitro . Initiated in 2013, the first multinational Phase II\n",
      "trial of anti-LINGO-1 antibodies in patients with acute optic neuritis has shown an effect on promoting nerve repair following optic neuritis .\n",
      "Ultimately, therapies that successfully promote remyelination and repair may be applicable across the spectrum of MS subtypes, including progressive\n",
      "forms of the disease . Tyrosine kinase inhibitors . Mastinib has completed a positive Phase IIb study in patients with primary and secondary\n",
      "progressive MS, the results of which are reported to include improvement in the Multiple Sclerosis Functional Composite (see pages 54 -) . A Phase III\n",
      "trial in this population is now in progress, and it may prove to be an oral treatment option for this more rare type of MS . Mastinib targets mast\n",
      "cells and inhibits several biochemical processes . It is used in the treatment of canine diseases and is also being evaluated in stroke, amyotrophic\n",
      "lateral sclerosis and Alzheimer's disease . Sphingosine-1 phosphate (S1P) receptor inhibitors . Multiple S1P receptor inhibitors are in Phase III\n",
      "development . If they are shown to target only certain modules of the receptor id est 1 and 5, it is hoped they will be associated with fewer side\n",
      "effects than those experienced with fingolimod, which has effects on multiple receptor units located in the heart and lungs, to name a few . S1P\n",
      "receptor products in Phase III studies include ponesimod, siponomod and ozanimod .\n",
      "\n",
      "Prediction:\n",
      " Mesenchymal tissue can be harvested from bone marrow, placental or adipose tissue, and multipotent\n",
      "mesenchymal stem cells expanded and purified in vitro. From only a few stem cells,\n",
      "billions/trillions of self-regenerating stem cells can be grown using specific nutrients (growth\n",
      "factors) and then readministered to the patient (intravenously or intrathecally) without the need\n",
      "for toxic conditioning regimens. Early data suggest these cells may have an ameliorating effect on\n",
      "inflammation in patients with MS.\n",
      "\n",
      "Reference:\n",
      "Anti-LINGO antibody is the first remyelination-promoting therapy to reach Phase II clinical trials\n",
      "in optic neuritis. Treatments that overcome molecular obstacles to remyelination may complement\n",
      "immune-directed therapies for MS in the future.\n",
      "\n",
      "####################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print_examples('sshleifer/distilbart-cnn-12-6', df_train)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "fSqOx7kdMoNJ"
   },
   "source": [
    "##### Print Val Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 131761,
     "status": "ok",
     "timestamp": 1610379275932,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "f7k8RzJgMoNK",
    "outputId": "ccdaf8ab-d19f-4272-dadd-e520fe95d3c2"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[+] model already present in cache\n",
      "\n",
      "(9781908541178, 'ch_6')\n",
      "As often as possible, acute pain syndromes must be reversed in a timely manner to limit the possibilities of developing a chronic pain condition, and\n",
      "pain-relieving strategies must be structured and coordinated to implement a prompt return to family, workplace and social activities . Anatomic\n",
      "structures involved in generating pain . Many anatomic factors can play a primary or a secondary role in the development and progression of low back\n",
      "pain syndromes . The most common causes of low back pain are mechanical in origin . Mechanical disorders of the lumbar spine are related to injury,\n",
      "overuse or deformity of a spinal structure . The most important traumatic factors in low back pain relate to soft tissue structures . Precise\n",
      "identification of the injured tissue, and the role of that injury in the consequent pain and dysfunction, can be frustratingly difficult . Problems\n",
      "occur in muscles, intervertebral discs, facet joints, ligaments or spinal nerves . Aging causes modification of these structures over time, and\n",
      "different parts of the spine tend to be at greater risk for change or injury during different decades of life . Early in life, muscle injuries are\n",
      "more frequent, while joint problems occur in the sixth decade of life (Table 3.1) . Paraspinal muscles are essential to postural stabilization and\n",
      "mobilization of the trunk, and consist of two main types . The small muscle group consists of two short intersegmental muscles: the interspinalis\n",
      "muscles that bridge the spinous processes and the intertransversarii that bridge the transverse processes . The multifidus and erector spinae form two\n",
      "large, polysegmental muscle groups . The multifidus is the most medial . Its origin is on the spinous processes, with insertions on the vertebral\n",
      "mamillary processes, the posterior superior iliac spine, the dorsal aspect of the sacrum and the posterior sacroiliac ligament . The erector spinae\n",
      "consists primarily of the longissimus thoracis and the ileocostalis lumborum (Figure 3.1) with a third small component, the spinalis dorsi, which only\n",
      "attaches to the spinous processes of L1, L2 and L3 . The erector spinae muscles originate on the lower ribs and thoracic transverse processes and\n",
      "insert on the lumbar vertebrae, the iliac crests and adjacent to the posterior superior iliac spines . Although muscle 'spasm' of the erector spinae\n",
      "in association with acute pain is common, pain referral and muscle spasm with focal tenderness (a trigger point) in the mid-portion of the quadratus\n",
      "lumborum muscle and/or a tender point on the mid-iliac crest is more often noted . This can be a consequence of pain referral from vertebral facet or\n",
      "discal strains at either the dorsolumbar origins or the iliolumbar insertions of the erector spinae muscles . The gluteal and piriformis muscles are\n",
      "shown in Figure 3.1 . The primary functions of the gluteal muscles are to support, stabilize and mobilize the hips and lower extremities in relation\n",
      "to the pelvis and the trunk . Possibly the most common manifestation of lumbar and lumbosacral pain referral is to the mid-portion of the gluteal\n",
      "muscles (buttocks) that overlie the piriformis muscle . This is accompanied by a palpable localized region of deep, tender muscle induration . Because\n",
      "of the thickness of the overlying gluteus maximus muscle, the fibers of which are parallel to (and indistinguishable from) the piriformis muscle\n",
      "fibers, it is not possible to determine by palpation if the piriformis muscle per se is the source of the localized muscle tenderness . A 'piriformis\n",
      "syndrome' is therefore somewhat problematic to identify and must be carefully distinguished from the more common, spinal discogenic basis for sciatic\n",
      "radiculopathy . A piriformis syndrome may result from scarring after a fall on the buttocks or as a consequence of pelvic or hip surgeries . MRI can\n",
      "be used to visualize the tender area in the buttocks and help to identify selective piriformis entrapments of the sciatic nerve .\n",
      "\n",
      "Prediction:\n",
      " Many anatomic factors can play a primary or a secondary role in the development and progression of\n",
      "low back pain syndromes. The most common causes of low back pain are mechanical in origin. The most\n",
      "important traumatic factors in low back pain relate to soft tissue structures.\n",
      "\n",
      "Reference:\n",
      "Mechanical disorders - muscle strain, spondylolisthesis, herniated intervertebral disc,\n",
      "osteoarthritis, spinal stenosis - are the most common causes of low back pain.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781912776726, 'ch4')\n",
      "Patients with glioblastoma should be cared for by a multidisciplinary team that includes a neurosurgeon, neuropathologist, neuroradiologist, medical\n",
      "and radiation oncologists, and possibly a neurologist, together with allied health professionals such as physiotherapists, occupational therapists and\n",
      "social workers . Involvement of a supportive care team including specialist nursing care is also mandatory in the palliative setting . Patients with\n",
      "glioblastoma have specific information needs . While the amount of information that patients want varies from person to person, and in some cases\n",
      "understanding may be impaired by cognitive deficits, patients and their carers need frank but compassionate information on diagnosis, prognosis,\n",
      "treatment options, recurrence and end-of-life care . News of a poor prognosis can be difficult to process initially . Patients need time to ask\n",
      "questions and receive honest answers . A combination of written and verbal information over several consultations and ongoing access to a well-\n",
      "resourced specialist nurse and psychologist or counselor are all important in this respect . Standard of care for newly diagnosed glioblastoma . The\n",
      "current standard of care for newly diagnosed glioblastoma is maximum surgical resection followed by radiotherapy and concomitant temozolomide and\n",
      "adjuvant temozolomide . Surgery is the initial therapeutic approach for tumor debulking and to obtain tissue for diagnosis . The aim of surgery is\n",
      "maximum tumor resection while maintaining neurological function . Risk versus benefit . The neurosurgeon's preoperative assessment of the patient's\n",
      "prognosis - which will depend, among other things, on the location of the glioblastoma and the patient's performance status - will determine the\n",
      "extent of resection . For example, if the tumor is near or involves eloquent (exempli gratia language, motor, vision) areas of the brain, a subtotal\n",
      "resection or tissue biopsy only may be considered a more appropriate option than aggressive total resection . The consequences of surgically acquired\n",
      "neurological deficits (exempli gratia language, cognitive, motor, coordination and visual deficits) can be significant . If surgical resection is not\n",
      "safe because of the tumor location or impaired performance status, a biopsy should be obtained if feasible . Surgical planning . MRI helps to estimate\n",
      "the operability of tumors and facilitates surgical planning . High-resolution 3D volumetric imaging sequences can help to assess tumor resectability\n",
      "and the optimal operative trajectory . Anatomic MRI can be integrated into surgical navigation software, where appropriate, together with functional\n",
      "and tractography sequences . Functional MRI (fMRI) measures dynamic blood oxygen level-dependent variations in brain activity . For the purpose of\n",
      "surgical planning, this usually requires the patient to perform specific tasks (task-based fMRI) . Most commonly, fMRI can assess language\n",
      "lateralization or motor cortical activation in relation to the tumor . fMRI is considered less reliable for accurate language localization, because\n",
      "the activation of language regions is complex, multifocal and not comprehensively explored by basic fMRI tasks . Diffusion tensor imaging (DTI) builds\n",
      "on standard diffusion-weighted imaging (see page 36) by including additional (a minimum of six) diffusion directions . These multidirectional data\n",
      "enable both the volume and the directionality of diffusion to be calculated . DTI tractography provides an approximation of the relations between the\n",
      "most eloquent white matter tracts and the tumor . Distances are usually expressed as estimates rather than exact (exempli gratia millimeter)\n",
      "measurements, because the depiction of white matter fibers can vary depending on the segmentation technique and threshold settings . Task-based fMRI\n",
      "and DTI tractography are valuable tools for localizing eloquent cortical and subcortical areas before glioma surgery (Figure 4.1), providing better\n",
      "accuracy than intraoperative stimulation mapping data . Complete tumor resection is not curative, but is associated with longer overall survival (OS)\n",
      "than partial resection; the worst outcomes are in patients with unresectable tumors .\n",
      "\n",
      "Prediction:\n",
      " The current standard of care for newly diagnosed glioblastoma is maximum surgical resection\n",
      "followed by radiotherapy and temozolomide. The aim of surgery is maximum tumor resection while\n",
      "maintaining neurological function. The consequences of surgically acquired neurological deficits can\n",
      "be significant. Complete tumor resection is not curative, but is associated with longer overall\n",
      "survival.\n",
      "\n",
      "Reference:\n",
      "The initial therapeutic approach is surgical tumor debulking and biopsy; maximum tumor resection\n",
      "should be attempted if neurological function can be maintained.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9783318066241, 'ch6')\n",
      "Marked hypovolemia may result in decreased urine output, renal failure and hypotension . Fluid rate and volume . In 1998, a case-control study\n",
      "compared hematocrit among patients with necrotizing versus mild AP . Hemoconcentration or the failure of the admission hematocrit to decrease at 24\n",
      "hours were strongly associated with pancreatic necrosis . The authors suggested that hemoconcentration was the cause of pancreatic necrosis through\n",
      "impaired pancreatic blood flow and recommended aggressive fluid resuscitation to improve outcomes in all patients with AP . In the following decade,\n",
      "guidelines and reviews addressing AP recommended aggressive fluid resuscitation as the standard of care . However, local complications such as\n",
      "pancreatic necrosis are associated with fluid sequestration, as intravascular liquid leaks to the retroperitoneum . This results in hemoconcentration\n",
      "and it has been suggested that an increased hematocrit is in fact a marker for local complications, not their cause (reverse causation bias) . In 2009\n",
      "and 2010, two studies were published by the same research group . These were open-label randomized controlled trials (RCTs) comparing a more\n",
      "aggressive versus a moderate fluid volume administration (10-15 vs 5-10 mL/kg/hour) and a more rapid versus a slower hemodilution (hematocrit < 35% vs\n",
      ">= 35% at 48 hours) in patients with severe AP according to the classic 1993 Atlanta criteria (presence of local complications and/or organ failure) .\n",
      "In both trials, the more aggressive approach was associated with worse outcomes, including decreased survival . These studies suggested that vigorous\n",
      "resuscitation is dangerous in patients with severe AP . The studies had some flaws, including being open-label single-center RCTs, with suboptimal\n",
      "randomization, an unexpectedly high rate of sepsis in patients with aggressive resuscitation and large differences in mortality between treatment\n",
      "groups despite a very small sample of patients, and they require validation . A recent open-label RCT conducted in the USA included patients with\n",
      "predicted mild AP (without SIRS criteria or OF at presentation) . Patients received aggressive (20 mL/kg bolus followed by 3 mL/kg/hour) or standard\n",
      "(10 mL/kg bolus followed by 1.5 mL/kg/hour) hydration with lactated Ringer's solution . The main outcome was clinical improvement within 36 hours, a\n",
      "composite variable which required all of the following to be fulfilled: decrease in hematocrit, BUN and creatinine from baseline; decrease in\n",
      "abdominal pain; and tolerance of oral nutrition . A higher proportion of patients treated with aggressive resuscitation showed clinical improvement at\n",
      "36 hours (70% vs 42%; p = 0.03) and the frequency of patients with persistent SIRS was lower . Unfortunately, the outcome variable was too dependent\n",
      "on hemodilution, which is not necessarily a marker of a better course of disease; patients receiving more aggressive resuscitation simply become\n",
      "hemodiluted more quickly . A study examining goal-directed fluid resuscitation (mainly based on serum BUN) did not find an association with improved\n",
      "outcomes, but it was probably underpowered because to a lower than expected incidence of SIRS . Well-designed RCTs are still needed to ascertain the\n",
      "role of aggressive and goal-directed fluid resuscitation . Currently, it is clear that fluid volumes and rates need to be tailored to individual\n",
      "patient requirements . Urine output is a particularly sensitive measure for detecting early hypovolemia due to fluid sequestration and increased\n",
      "losses . Decreased urine output and blood pressure due to true hypovolemia tend to respond quickly to aggressive fluid resuscitation; however,\n",
      "distributive shock results in refractory cardiovascular and renal failure regardless of fluid volume, and will require vasoactive drugs in an\n",
      "intensive care unit setting . Fluid type . Both an open-label and a triple-blind RCT have demonstrated that fluid resuscitation using lactated\n",
      "Ringer's solution (a balanced salt solution) is associated with a decreased inflammatory response when compared with fluid resuscitation with normal\n",
      "saline (with a high chloride content) . According to in vitro experiments, it seems that this anti-inflammatory effect depends on lactate . However,\n",
      "both studies included a small number of patients, and the influence of lactated Ringer's solution on important outcomes such as OF or mortality is\n",
      "unknown .\n",
      "\n",
      "Prediction:\n",
      " Marked hypovolemia may result in decreased urine output, renal failure and hypotension. In 1998, a\n",
      "case-control study compared hematocrit among patients with necrotizing versus mild AP. In both\n",
      "trials, the more aggressive approach was associated with worse outcomes, including decreased\n",
      "survival.\n",
      "\n",
      "Reference:\n",
      "There is a lack of well-designed randomized clinical trials addressing the best fluid volume rate to\n",
      "improve outcomes.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797662, 'ch07')\n",
      "Management of advanced and metastatic disease . A core principle in the management of solid tumors is to consider control of both the primary and\n",
      "metastatic disease . Several clinical scenarios occur in bladder cancer . Cancers that are clearly confined to the bladder can potentially be cured if\n",
      "the primary tumor can be removed or ablated, through surgery, radiation therapy or multimodality approaches, and there is no metastatic disease;\n",
      "5-year survival rates are about 70% . Management of these cancers is discussed in chapter on 'Management of non-muscle-invasive disease' . Locally\n",
      "advanced cancers and tumors that have spread to loco-regional lymph nodes are associated with an increased risk of local relapse and a higher risk of\n",
      "micrometastatic disease at diagnosis . Five-year survival is about 35% . Lymph node involvement is identified through lymph node dissection or\n",
      "accurate imaging . The primary cancer may still be amenable to local therapy, and is potentially curable in the absence of distant metastases .\n",
      "Optimum systemic therapy with cisplatin-based chemotherapy is standard of care for patients with adequate renal function who are suitable for\n",
      "chemotherapy . Cancers predominantly involving the bladder but where there is small-volume overt metastatic disease are unlikely to be cured with\n",
      "currently available modalities; treatment is therefore palliative in intent, which must be clearly understood from the outset . Five-year survival for\n",
      "patients with metastatic disease is approximately 5%, although this varies depending on the bulk of disease, response to therapy and patient factors,\n",
      "including comorbidities . The mainstay of therapy is systemic treatment to control the progression of metastatic disease although management of the\n",
      "primary cancer may be necessary to alleviate symptoms and to prevent future complications such as pain, intractable hematuria and upper urinary tract\n",
      "obstruction . Surgery or radiation therapy may therefore be necessary for management of the primary tumor, and sometimes for management of metastatic\n",
      "disease . Cancers where the bulk of disease is metastatic are currently incurable; the intention of treatment is therefore palliative . Ablative local\n",
      "therapies such as surgery or radiation therapy should only be used to ameliorate current and potential issues that compromise quality of life . All\n",
      "these strategies are predicated on whether the patient is able to tolerate the proposed treatment, and other factors such as comorbidities may require\n",
      "modification of the treatment plan . Treatment decisions usually require multidisciplinary input . A key component of such discussions should be\n",
      "whether participation in a clinical trial is possible and an appropriate option for the patient to consider . This chapter summarizes current clinical\n",
      "recommendations for the systemic therapy of loco-regional advanced or metastatic disease . The treatment landscape and resulting recommendations are\n",
      "likely to change over the next few years as clinical trials are completed, particularly those of immunotherapies (see page 71) . Systemic therapy for\n",
      "metastatic bladder cancer . The activity of various cytotoxic drugs such as doxorubicin (Adriamycin), methotrexate, vinblastine and cisplatin against\n",
      "urothelial bladder cancer has been recognized since the 1970s . Response rates with cisplatin monotherapy were initially reported to be as high as\n",
      "40%, although subsequent studies showed that response rates of 10-15% were more realistic . Other drugs such as paclitaxel and gemcitabine were also\n",
      "subsequently shown to have activity as monotherapies . The first combination chemotherapy regimen to be widely used in clinical practice was\n",
      "cisplatin, methotrexate and vinblastine (CMV), which showed an overall response rate of 56% in a small single-arm study, half of which were complete\n",
      "remissions (notably in the era before computed tomography) .\n",
      "\n",
      "Prediction:\n",
      " A core principle in the management of solid tumors is to consider control of both the primary and\n",
      "metastatic disease. Management of these cancers is discussed in chapter on 'Management of non-\n",
      "muscle-invasive disease'\n",
      "\n",
      "Reference:\n",
      "Management of both local and distant metastatic disease should be considered.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797723, 'chp3')\n",
      "How cancer immunotherapy works . In the context of cancer, the term immunotherapy encompasses a variety of approaches, targeting diverse immunologic\n",
      "targets . The history of immuno-oncology . The concept of immuno-oncology dates back more than 100 years, to 1893 (Figure 3.1) . In that year, William\n",
      "Coley, an American surgeon and cancer researcher, observed remission of cancer in patients with postoperative bacterial infections, and suggested that\n",
      "activation of the immune system must play a role in combating cancer . Subsequently, in 1909, Paul Ehrlich suggested that the immune system must play\n",
      "an important role in preventing the development of cancer . However, it was not until the mid-20th century when Lewis Thomas and Frank MacFarlane\n",
      "Burnet hypothesized that the immune system is capable of eliminating cancerous cells through a process known as immune surveillance, and that this\n",
      "process depends on recognition of tumor-associated antigens by the immune system . Subsequently, through the laboratory work of Lloyd Old and Robert\n",
      "Schreiber, the concept of immune surveillance has evolved into 'immunoediting', reflecting the ability of tumor cells to evade the immune system .\n",
      "Increasing understanding of the underlying mechanisms of immunoediting has identified numerous potential therapeutic targets, some of which - notably\n",
      "immune checkpoint inhibition as first demonstrated by James Allison in the 1990s - are already yielding promising results in clinical practice .\n",
      "Indeed, in 2013, cancer immunotherapy was cited as the 'breakthrough of the year' by the journal Science . What types of tumor are potentially\n",
      "susceptible to immuno-oncology? . Clearly, the potential sensitivity of a given cancer to immuno-oncology therapies will depend on the ability of the\n",
      "tumor to trigger an immune response (immunogenicity) . Cancer is characterized by an accumulation of genetic mutations, many of which result in the\n",
      "expression of cancer-specific antigens that can bind to major histocompatibility complex (MHC) class I molecules on the cancer cell surface . These\n",
      "antigen-MHC complexes can be recognized by cytotoxic CD8+ lymphocytes, that, if activated, could potentially mount an immune response against the\n",
      "tumor . As a result, tumors with high somatic mutation rates may be more susceptible to immuno-oncology therapies than those with lower mutation rates\n",
      ". Somatic mutation rates differ markedly, both between tumor types and within an individual tumor type: the rate may vary more than 1000-fold between\n",
      "tumors with the highest and lowest rates (Figure 3.2) . The highest rates are seen in cancers of the skin, lung, bladder and stomach, while the lowest\n",
      "are seen in hematologic and pediatric cancers . It is noteworthy that the highest rates occur in tumors that are induced by carcinogens such as\n",
      "tobacco smoke or ultraviolet light . Potential targets for cancer immunotherapy . A variety of cancer immunotherapy strategies are currently being\n",
      "investigated, or have already entered clinical practice . These are conventionally classified as passive or active immunotherapies, according to their\n",
      "ability to activate an immune response against tumor cells (Table 3.1), although this classification does not adequately reflect the complexity of\n",
      "drug-host-tumor interactions . As a result, it has been suggested that immunotherapies should be classified according to their antigen specificity;\n",
      "however, even therapies initially directed against a single antigen may eventually become responsive to multiple antigens, a phenomenon known as\n",
      "epitope spreading . Passive immunotherapies . Tumor-targeting monoclonal antibodies . Monoclonal antibodies (mAbs) that specifically target malignant\n",
      "cells are among the best characterized forms of cancer immunotherapy . These may act in a number of ways, including . inhibition of signaling pathways\n",
      "in tumor cells . delivery of conjugated cytotoxins or radionuclides to tumor sites . opsonization of tumor cells and activation of antibody-dependent\n",
      "cell-mediated cytotoxicity (ADCC), antibody-dependent phagocytosis and complement-mediated cytotoxicity . bispecific T-cell engagers (BiTEs ®; Amgen)\n",
      "consisting of single-chain variable fragments from two antibodies targeting a tumor-associated antigen (TAA) and a T-cell surface antigen . Examples\n",
      "of mAbs that act via these processes are shown in Table 3.2 .\n",
      "\n",
      "Prediction:\n",
      " In the context of cancer, the term immunotherapy encompasses a variety of approaches, targeting\n",
      "diverse immunologic targets. The concept of immuno-oncology dates back more than 100 years, to 1893.\n",
      "Increasing understanding of the underlying mechanisms of immunoediting has identified numerous\n",
      "potential therapeutic targets.\n",
      "\n",
      "Reference:\n",
      "The potential sensitivity of a given cancer to immunotherapy depends on the immunogenicity of the\n",
      "tumor, which is related to the somatic mutation rate within tumor cells.- The highest mutation rates\n",
      "are seen in cancers of the skin, lung, bladder and stomach, rendering these tumor types more\n",
      "sensitive to immunotherapy.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797471, 'ch02')\n",
      "Pathophysiology and clinical stages . Advances in the management of heart failure (HF) over the past 20 years have been informed by a better\n",
      "understanding of its pathophysiology . There are few situations in cardiology where treatment has been as closely linked to an appreciation of the\n",
      "underlying science . Vicious cycle of heart failure . HF is a disease of inappropriate adaptation to injury . The body has a limited range of\n",
      "compensatory responses to circulatory impairment, mainly vasoconstriction and sodium and water retention (see below) . In general, however, these\n",
      "adjustments to hypovolemia are poorly suited to pump failure, and increases in the preload and afterload of the failing heart lead to worsening HF\n",
      "(Figure 2.1) . Neurohormonal pathways activated in HF include the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system (RAAS)\n",
      "and the natriuretic peptide (NP) system . They play a significant role in the pathophysiology of HF, and pharmacological interventions have been\n",
      "developed accordingly (see Chapter 7) . Sympathetic nervous system . Sympathetic activation of the adrenergic system leads to vasoconstriction, which\n",
      "increases the resistance to blood flow and helps to maintain arterial pressure in the early stages of HF when cardiac output is reduced . However,\n",
      "vasoconstriction also increases the afterload on the heart, leading to a worsening of HF (see Figure 2.1) . Renin-angiotensin-aldosterone system .\n",
      "Enhanced sympathetic outflow also activates the RAAS (Figure 2.2) . Renin release from the kidneys causes increased formation of angiotensin I from\n",
      "angiotensinogen and, via the action of angiotensin-converting enzyme (ACE), angiotensin II . Angiotensin II causes systemic vasoconstriction and acts\n",
      "on the adrenal cortex to produce aldosterone, leading to sodium and water retention . In addition, aldosterone (which may be released even in the\n",
      "setting of ACE inhibition) contributes to myocardial and vascular fibrosis . Sympathetic stimulation also releases antidiuretic hormone, which leads\n",
      "to retention of free water and contributes to dilutional hyponatremia . Natriuretic peptide system . The natriuretic peptide family consists of A\n",
      "(atrial) and B (brain) type natriuretic peptides (ANP and BNP), which are produced by cardiomyocytes in response to atrial and ventricular stretch,\n",
      "and C type natriuretic peptide, which is secreted by endothelial and renal cells . NPs, mainly BNP, lead to increased sodium excretion and\n",
      "vasodilation, especially in the early phases of HF . BNP also has anti-remodeling properties . The biological action of BNP is mediated through\n",
      "membrane-bound natriuretic peptide receptors (NPRs) and the peptide is degraded by neutral endopeptidase (including neprilysin) . It is postulated\n",
      "that HF is a state of relative BNP deficiency caused by both lack of biologically active peptide and resistance at a receptor level . In end-stage HF,\n",
      "the peptides may not be released because of myocyte loss . Other pathways also reflect an inappropriate response to injury . Cytokine release is\n",
      "increased in HF, leading to a variety of consequences including apoptosis . The role of these as contributors to the progression of HF, rather than a\n",
      "correlate, is debated . Certainly, the failure of tumor necrosis factor (TNF) inhibitors to improve outcome argues against a causative role .\n",
      "Remodeling of the myocardium . Global and local responses to maladaptive stimuli lead to myocardial remodeling, namely increased myocardial volume and\n",
      "mass and a net loss of myocytes .\n",
      "\n",
      "Prediction:\n",
      " Advances in the management of heart failure (HF) over the past 20 years have been informed by a\n",
      "better understanding of its pathophysiology. HF is a disease of inappropriate adaptation to injury.\n",
      "The body has a limited range of compensatory responses to circulatory impairment. These adjustments\n",
      "to hypovolemia are poorly suited to pump failure. Increases in the preload and afterload of the\n",
      "failing heart lead to worsening HF.\n",
      "\n",
      "Reference:\n",
      "Heart failure (HF) is a disease of response to injury, which is initially appropriate and becomes\n",
      "inappropriate.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797815, 'chp9')\n",
      "Management of myeloproliferative neoplasm blast phase . Most myeloproliferative neoplasms (MPNs) are chronic conditions that remain clinically stable\n",
      "for many years; however, the condition may progress to acute leukemia in a minority of patients, referred to as MPN blast phase (MPN-BP) . This\n",
      "transformation most commonly occurs in patients with myelofibrosis, in whom transformation rates of 15-30% have been reported, compared with 1-4% for\n",
      "patients with essential thrombocythemia (ET) and 4-9% for those with polycythemia vera (PV) . Typically, patients with ET or PV initially develop\n",
      "post-ET or post-PV myelofibrosis, which may subsequently undergo transformation to MPN-BP, although in rare cases these conditions may transform\n",
      "directly into MPN-BP without an intermediate myelofibrotic stage . Risk factors for the development of MPN-BP include leukocytosis, thrombocytopenia\n",
      "and unfavorable karyotype (Table 9.1) . There are no specific diagnostic criteria for MPN-BP . The principal criterion is the same as for de novo\n",
      "acute myeloid leukemia (AML): more than 20% blasts in bone marrow or peripheral blood . Persistence is also important if only peripheral blood blasts\n",
      "are considered . Importantly, acceleration or progression of myelofibrosis is usually apparent before the development of overt leukemia . Signs of\n",
      "this include . worsening cytopenia or anemia . worsening of constitutional symptoms . progressive and resistant splenomegaly . increasing numbers of\n",
      "blasts in bone marrow and peripheral blood . rising lactate dehydrogenase . new cytogenetic or molecular marker . In addition, recent evidence\n",
      "suggests that progression during treatment with Janus kinase inhibitors is associated with a risk of MPN-BP . MPN-BP is associated with a poor\n",
      "prognosis: median survival is 2-6 months, although this may be prolonged by intensive treatment and prompt recourse to stem cell transplantation (SCT)\n",
      ". There is no standard of care for MPN-BP, and many of the current treatment regimens (Table 9.2) are derived from experience in AML . Induction\n",
      "chemotherapy and SCT . In general, MPN-BP should only be treated with induction chemotherapy when allogeneic SCT is planned in eligible patients . The\n",
      "induction chemotherapy regimens are the same as those used in AML, and response rates are similar to those seen in poor-risk AML patients: typically,\n",
      "complete response (CR) and CR with incomplete count recovery (CRi) rates are 40-50%, although rates of approximately 70% have been reported with a\n",
      "combination of cytosine arabinoside and anthracycline . However, these responses are not durable, having a median duration of approximately 5 months .\n",
      "Eligible patients should therefore undergo SCT as soon as possible . The importance of this is highlighted by a study in which median overall survival\n",
      "in patients who completed allogeneic SCT following CR/CRi with induction chemotherapy was 47 months, compared with 9.4 months in those who achieved a\n",
      "CR/CRi but did not go on to SCT . Two-year overall survival rates were 47% and 17%, respectively . Achieving a CR is essential for successful SCT . In\n",
      "one study, 8 of 13 patients proceeded to SCT after induction chemotherapy and were followed for a median of 20 months . All five who achieved CR had\n",
      "returned to chronic MPN at the time of SCT but remained in remission, whereas 2 of 3 patients with persistent marrow or circulating blasts died .\n",
      "There is growing interest in post-transplant immunomodulation with donor lymphocyte infusion or drugs such as hypomethylating agents . Less-intensive\n",
      "chemotherapy . Patients with MPN-BP who are not eligible for induction chemotherapy or SCT may benefit from treatment with hypomethylating agents . In\n",
      "one study involving 54 patients with MPN-BP or a condition suggestive of myelodysplastic syndrome, treatment with azacitidine resulted in an overall\n",
      "response rate (CR + CRi + partial response) of 28% after a median of 20 months' follow-up, and median overall survival was 8 months in the MPN-BP\n",
      "group . However, support for this approach currently comes mainly from small case series .\n",
      "\n",
      "Prediction:\n",
      " Myeloproliferative neoplasm blast phase (MPN-BP) may progress to acute leukemia in a minority of\n",
      "patients. MPN-BP is associated with a poor prognosis: median survival is 2-6 months. Risk factors\n",
      "for the development of MPN-BP include leukocytosis, thrombocytopenia and unfavorable karyotype.\n",
      "\n",
      "Reference:\n",
      "Signs of accelerating myelofibrosis may precede the development of overt leukemia.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9783318068207, 'hh-7')\n",
      "Nonetheless, a BRAF mutation is a negative prognostic indicator . US and European guidelines mandate extended RAS and BRAF testing and MSI analysis\n",
      "using the most appropriate methods (Figure 5.1) . NGS provides the widest genetic coverage and most cost-effective solution . Where gene chips for\n",
      "multiple genes are utilized, extra information may be gained . In particular, mutations in other genes (PIK3CA, PTEN) and overexpression of HER2\n",
      "(ERBB2) may be detected, as may other novel biomarkers . HER2 overexpression has been detected in around 3.5% of CRCs . Promising responses to anti-\n",
      "HER2 therapies have been reported in clinical trials (HERACLES-A, HERACLES-B and HERACLES-RESCUE) . Patients with MSI-H CRC tumors respond to therapy\n",
      "with pembrolizumab . The group of potentially benefiting patients has now been expanded to include patients with high TMB, which is emerging as an\n",
      "important predictive biomarker for response to immune checkpoint inhibitor drugs in the subset of MMR-deficient (MSI-H) CRC . TMB can be detected by\n",
      "NGS technology (see page 45) . The use of validated biomarkers and those currently being investigated is summarized in Table 5.2 . Liquid biopsy .\n",
      "Undoubtedly, liquid biopsies - being minimally invasive - will become more commonly used to determine biomarkers . Already, the presence of ctDNA is a\n",
      "predictor of relapse . Although ctDNA may be utilized predictively in the future to guide patient management, at present it has relatively high false-\n",
      "positive and -negative rates . Current ESMO and ASCO guidelines do not recommend its use for the initial diagnosis of, or as a predictive biomarker\n",
      "for, CRC . As NGS and newer technologies overcome the technical shortcomings, it is highly likely that liquid biopsy will find a more significant role\n",
      "in diagnostics, which will necessitate new guidelines . Melanoma is a highly mutated malignancy, with mutations documented in all subtypes (Table 5.3)\n",
      ". The KIT mutation is associated with chronic sun damage . The BRAF mutation is present in 11% of patients with mucosal melanoma, NRAS mutation in 5%\n",
      "and KIT mutation in 15-20% . From a molecular point of view, uveal melanoma is a distinct condition characterized, in 50% of patients, by the presence\n",
      "of a GNAQ mutation . The presence of BRAF and NRAS mutations has not been described in uveal melanoma . The serine/threonine kinase BRAF is involved\n",
      "in the downstream signaling of the RTK and RAS proteins . Approximately half of melanomas show BRAF point mutations (Figure 5.2) . In the majority of\n",
      "cases, a valine at position 600 is mutated to glutamic acid or lysine (BRAF p . V600E and BRAF p . V600K); both mutations are associated with kinase\n",
      "activation that results from relieving an intramolecular autoinhibitory interaction between the activation segment and P-loop of the protein . The\n",
      "events result in abnormal activation of the MAPK pathway, including the serine/threonine kinases MEK1/2, ERK1/2, and many downstream targets,\n",
      "resulting in many hallmarks of cancer, such as proliferation, migration, defense from apoptosis, and cellular metabolism . BRAF mutations are most\n",
      "common in the nodular and superficial spreading melanoma types, and they are rare in acral lentiginous (5-10% of cases) and non-cutaneous melanomas .\n",
      "BRAF mutation correlates with distinct histopathological features, such as intraepidermal melanoma nest formation and a larger rounder border of the\n",
      "tumor with the surrounding skin, suggesting surrogate markers can be used to select patients for molecular testing . BRAF mutations also arise more\n",
      "commonly in patients who are younger at presentation and those with lymph node metastasis (rather than satellite tumors or visceral metastasis) . BRAF\n",
      "inhibitors can lead to remarkable early tumor responses in melanoma, though these may be of short duration in some patients . Approximately 20% of\n",
      "patients with mutant BRAF melanoma show no response, and most patients treated with monotherapy relapse, with a median PFS of 8-9 months . Vemurafenib\n",
      "is an orally available small molecule kinase inhibitor with activity against BRAF with the p . V600E mutation; its indication is restricted to\n",
      "melanoma patients with a demonstrated BRAF p .\n",
      "\n",
      "Prediction:\n",
      " US and European guidelines mandate extended RAS and BRAF testing and MSI analysis using the most\n",
      "appropriate methods. A BRAF mutation is a negative prognostic indicator. NGS provides the widest\n",
      "genetic coverage and most cost-effective solution.\n",
      "\n",
      "Reference:\n",
      "Melanoma is a highly mutated malignancy, with mutations - including BRAF, NRAS and KIT - documented\n",
      "in all melanoma subtypes.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797815, 'chp4')\n",
      "Management of essential thrombocythemia . The myeloproliferative neoplasms (MPNs) each present their own therapeutic challenges, and treatment should\n",
      "be tailored to the individual . However, the following principles apply to the management of all MPNs . low-dose aspirin should be considered unless\n",
      "contraindicated . cardiovascular risk factors such as hypertension or dyslipidemia should be treated aggressively, and smoking cessation actively\n",
      "promoted . Aims of treatment . Essential thrombocythemia (ET) is characterized by vascular features, including both thrombosis and paradoxical\n",
      "bleeding . In addition to the risk of major vessel thrombosis, thrombosis in the microcirculation (most likely transient) can give rise to symptoms\n",
      "such as red and painful extremities (erythromelalgia; Figure 4.1), headache, paresthesia, loss of vision or hearing and transient ischemic attack .\n",
      "Given this risk of thrombosis and hemorrhage, a key aim in the treatment of ET is to prevent blood clotting and bleeding; however, it is also\n",
      "important to alleviate any problematic symptoms . Stratification of treatment according to risk . As described in Chapter 3, the risk of thrombosis in\n",
      "ET is assessed on the basis of age and previous history of thrombosis . Thus, a patient below the age of 60 years with no previous history of\n",
      "thrombosis would be considered at low risk of vascular complications, whereas an older patient or one with previous thrombosis is considered to be at\n",
      "high risk . Similarly, Janus kinase 2 (JAK2) mutations are associated with a higher risk of thrombosis than are calreticulin (CALR) mutations, and may\n",
      "therefore be considered an additional risk factor for thrombosis in patients with ET (Figure 4.2), although this has yet to be fully incorporated into\n",
      "clinical practice . The choice of treatment depends on the patient's risk level . In general, patients at the lowest level of risk defined by the\n",
      "International Prognostic Score for Essential Thrombocythemia (IPSET) scoring system (Table 3.6, page 38) - younger patients without JAK2 mutations, no\n",
      "cardiovascular risk factors and no history of thrombosis - can often be managed by observation only, and they may not require aspirin (yet to be\n",
      "validated in clinical practice) . Low-risk patients with JAK2 mutations, or cardiovascular risk factors in the absence of JAK2 mutations, should\n",
      "perhaps be treated with aspirin . As a general principle, all high-risk patients should be treated with aspirin (unless contraindicated) and\n",
      "cytoreductive therapy to reduce the platelet count . The National Comprehensive Cancer Network guidelines for the management of ET are summarized in\n",
      "Figure 4.3 . Management of low-risk patients . Treatment to reduce cardiovascular risk factors, and promotion of a generally healthy lifestyle, may be\n",
      "sufficient intervention for very-low-risk patients . Smoking cessation should be actively promoted because cigarette smoking has been shown to be an\n",
      "independent risk factor for thrombosis in patients with ET . Low-dose aspirin has been shown to reduce both microvascular symptoms (exempli gratia\n",
      "erythromelalgia) and transient neurological and visual disturbances such as hemiparesis, scintillating scotomas, amaurosis fugax (transcient monocular\n",
      "blindness) and seizures . There is also evidence that antiplatelet therapy reduces the risk of venous thrombosis in patients with JAK2 V617F mutations\n",
      "and cardiovascular risk factors (arterial thrombosis) . Higher doses of aspirin (up to 500 mg daily) may be required in patients with acute\n",
      "erythromelalgia .\n",
      "\n",
      "Prediction:\n",
      " Essential thrombocythemia (ET) is characterized by vascular features, including both thrombosis and\n",
      "paradoxical bleeding. Low-dose aspirin should be considered unless contraindicated. cardiovascular\n",
      "risk factors such as hypertension or dyslipidemia should be treated aggressively, and smoking\n",
      "cessation actively promoted.\n",
      "\n",
      "Reference:\n",
      "Patients at the lowest level of risk (age < 60 years, no history of thrombosis, JAK2 V617F-negative,\n",
      "no cardiovascular risk factors) can be managed by observation alone. Other low-risk patients should\n",
      "receive low-dose aspirin.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541277, 'ch_11')\n",
      "A syndrome initially ascribed to hydantoins including PHT (fetal hydantoin syndrome), but now known to occur with other AEDs including CBZ and VPA,\n",
      "consists of facial dimorphism, cleft lip and palate, cardiac defects, digital hypoplasia and nail dysplasia . There are no clear data indicating\n",
      "differences in safety among PHT, CBZ, PB and PRM . Current evidence suggests that the risk of major congenital malformations is two to four times\n",
      "higher with the use of VPA than with other AEDs such as CBZ and LTG . Absolute rates have ranged from 6% to 11%, although the risk may be minimized by\n",
      "keeping daily doses at or below 1000 mg . High-dose exposure to VPA in utero may impair later cognitive function . The teratogenic risk associated\n",
      "with LTG monotherapy is low and is similar to that associated with CBZ, although preliminary data suggest the possibility of greater risk of major\n",
      "malformations at higher dosage . There are still insufficient data regarding the safety of other modern AEDs . After birth . The older enzyme-inducing\n",
      "AEDs (CBZ, PHT, PB and PRM) can cause transient and reversible deficiency in vitamin K1-dependent clotting factors in the neonate . The risk of\n",
      "intracerebral hemorrhage increases if the birth is traumatic . Accordingly, some clinicians believe that babies at risk should receive intramuscular\n",
      "vitamin K1 immediately after birth, and mothers should take oral vitamin K1, 10 mg daily, for the last few weeks of pregnancy . After delivery, all\n",
      "mothers should be encouraged to breastfeed their babies . The concentrations of PHT, CBZ and VPA in breast milk are low and not usually harmful . PB,\n",
      "PRM and LTG can accumulate in the breastfed baby because of slow elimination . Gabapentin (GBP) and vigabatrin (VGB) are unlikely to accumulate in\n",
      "infants as these AEDs are excreted mainly unchanged in the urine . There are few data relating to the other newer AEDs . As a general rule, if the\n",
      "baby is noted to be drowsy or sedated, breastfeeding should be alternated with bottle feeding or stopped altogether . Pregnancy registries . The\n",
      "Antiepileptic Drug Pregnancy Registry was established in the USA in 1996 to determine prospectively the risk of major malformations from AEDs . Women\n",
      "with epilepsy who become pregnant should call the toll-free number (1 888 233 2334) to enroll . Physicians cannot enroll patients; the woman herself\n",
      "must call as part of the informed consent process . There are three brief interviews: an initial 15 minutes, 5 minutes at 7 months' gestation and 5\n",
      "minutes 2-4 weeks after birth . In Europe, a similar project is under way . This registry requires input from the attending clinician and not the\n",
      "patient . The European Registry of Antiepileptic Drugs and Pregnancy (EURAP) is a consortium of independent research groups that have agreed on a\n",
      "common protocol for a prospective assessment of pregnancy outcome . The registry has now expanded beyond Europe to include Australia, Japan and other\n",
      "Asian countries . All physicians who care for women taking AEDs during pregnancy are invited to contribute . They can contact their individual\n",
      "national coordinators or the central project commission via dbattino@istituto-besta . There is also an active prospective pregnancy register in the UK\n",
      ". Elderly patients . Old age is now the most common time in life to develop epilepsy . Approximately 1.5% of the population over the age of 70 years\n",
      "is diagnosed with active epilepsy . The number of elderly people diagnosed with epilepsy is set to rise further with the aging of the population .\n",
      "Nearly all de-novo seizures in elderly people are partial-onset with or without secondary generalization . Underlying factors can be identified in a\n",
      "greater proportion of elderly patients than younger patients, and include cerebrovascular disease, dementia and tumor . New-onset idiopathic syndromes\n",
      "are rare . Diagnosis of epilepsy can be challenging and may depend on a witnessed event . Complex partial seizures presenting as confusion may be\n",
      "misdiagnosed as psychiatric symptoms . Postictal confusion can be prolonged in the elderly and may contribute to physical injury sustained during a\n",
      "seizure . AEDs are the mainstay of treatment, and are effective in most patients . Complete seizure control can be expected in more than 70% of\n",
      "elderly patients .\n",
      "\n",
      "Prediction:\n",
      " Current evidence suggests that the risk of major congenital malformations is two to four times\n",
      "higher with the use of VPA than with other AEDs such as CBZ and LTG. High-dose exposure to VPA in\n",
      "utero may impair later cognitive function. There are no clear data indicating differences in safety\n",
      "among PHT, CBZ, PB and PRM.\n",
      "\n",
      "Reference:\n",
      "The risk of major malformations in babies exposed in utero seems to be greater with sodium valproate\n",
      "(VPA) than with other AEDs.\n",
      "\n",
      "####################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print_examples('sshleifer/distilbart-cnn-12-6', df_val)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "heading_collapsed": true,
    "id": "UTUY8QgQa2WM"
   },
   "source": [
    "##### Print Test Examples"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "executionInfo": {
     "elapsed": 155507,
     "status": "ok",
     "timestamp": 1610379299681,
     "user": {
      "displayName": "Marco Pietro Abrate",
      "photoUrl": "https://lh3.googleusercontent.com/a-/AOh14Gjh-8YF-8BlnrkN9mLZ0xfVOWfOh7kYncpYRv-Y=s64",
      "userId": "15422244832836998434"
     },
     "user_tz": -60
    },
    "hidden": true,
    "id": "D9rpcejOa2WO",
    "outputId": "9771e868-a233-4c5e-f925-b490fc5cc1ce"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[+] model already present in cache\n",
      "\n",
      "(9781908541277, 'ch_8')\n",
      "Pharmacokinetics and drug-drug interactions . As its half-life is shorter than that of PB, concentrations of PB are usually higher than those of PRM .\n",
      "Like PB, PRM is a powerful enzyme inducer . Sodium valproate (VPA) . The anticonvulsant property of VPA was recognized serendipitously in 1963 when it\n",
      "was used by Pierre Eymard as a solvent for a number of other compounds . VPA exerts its antiepileptic property, at least in part, by limiting\n",
      "sustained repetitive firing by a use- and voltage-dependent effect on sodium channels . It also facilitates the effects of the inhibitory\n",
      "neurotransmitter GABA . VPA is now established as effective over the complete range of seizure types, with particular value in the idiopathic\n",
      "generalized epilepsies . The starting dose for adults and adolescents should be 500 mg once or twice daily . Alterations thereafter can be made\n",
      "according to the clinical status of the patient . Divalproex sodium (a combination of valproic acid and VPA) can also be given twice daily . As the\n",
      "drug can take several weeks to become fully effective, frequent dose adjustments shortly after therapy is started may be unwarranted . Because VPA\n",
      "does not exhibit a clear-cut concentration-effect-toxicity relationship and daily variations in concentration at a given dose are wide, routine\n",
      "monitoring is unhelpful unless closely correlated with the patient's clinical situation . A few patients need and tolerate serum concentrations up to\n",
      "150 mg/liter . Side effects . Unpleasant or distressing side effects include dose-related tremor, weight gain due to appetite stimulation, thinning or\n",
      "loss of hair (usually temporary) and menstrual irregularities including amenorrhea . Some young women develop polycystic ovary syndrome associated\n",
      "with obesity and hirsutism . Rarely, stupor and encephalopathy associated with hyperammonemia can occur . The insidious development of parkinsonism\n",
      "has also been reported, although this effect reverses on VPA withdrawal . Hepatotoxicity, histologically a microvesicular steatosis similar to that\n",
      "found in Reye's syndrome, affects fewer than 1 in 20 000 exposed individuals . This appears to be a particular concern in children under 3 years of\n",
      "age receiving AED polypharmacy, some of whom will have a coexistent metabolic defect . Other sporadic problems include thrombocytopenia and acute\n",
      "pancreatitis . An important concern in women of childbearing potential is an increased dose-dependent risk of major malformations in offspring exposed\n",
      "to VPA during the first trimester of pregnancy . Data from prospective pregnancy registries suggest the risk may be more than 10%, including an\n",
      "estimated 1-3% risk of neural tube defects, at high dosage (> 1000 mg daily) . Women of childbearing potential should not be started on VPA without\n",
      "specialist neurological advice . High-dose VPA has also been linked to cognitive impairment in children who were exposed to the drug in utero .\n",
      "Pharmacokinetics and drug-drug interactions . VPA can inhibit a range of hepatic metabolic processes, including oxidation, conjugation and epoxidation\n",
      "reactions . Targets include other AEDs, particularly PHT, PB, the active epoxide metabolite of CBZ, and LTG . VPA does not, however, interfere with\n",
      "the hormonal components of the oral contraceptive pill . Modern antiepileptic drugs . After a hiatus of nearly 20 years, 16 new AEDs and two devices -\n",
      "the vagus nerve stimulator and deep brain stimulator - have received licenses for the adjunctive treatment of refractory epilepsy, the last so far\n",
      "only in Europe . Gabapentin (GBP), lacosamide (LCM), LTG, levetiracetam (LEV), oxcarbazepine (OXC), pregabalin (PGB), tiagabine (TGB), TPM and\n",
      "zonisamide (ZNS) are widely available for partial seizures . Rufinamide (RFN) has been licensed in Europe and the USA for adjunctive treatment of\n",
      "seizures in Lennox-Gastaut syndrome . Eslicarbazepine acetate (ESL) is licensed in Europe as adjunctive treatment for partial seizures with or without\n",
      "secondary generalization . Retigabine (RTG; ezogabine in the USA) and perampanel (PER) have recently been approved for use in Europe and the USA for\n",
      "the same indication .\n",
      "\n",
      "Prediction:\n",
      " The anticonvulsant property of sodium valproate (VPA) was recognized serendipititously in 1963 when\n",
      "it was used by Pierre Eymard as a solvent for a number of other compounds. VPA exerts its\n",
      "antiepileptic property, at least in part, by limiting sustained repetitive firing by a use- and\n",
      "voltage-dependent effect on sodium channels. It also facilitates the effects of the inhibitory\n",
      "neurotransmitter GABA. VPA is now established as effective over the complete range of seizure types,\n",
      "with particular value in idiopathic generalized epilepsies.\n",
      "\n",
      "Reference:\n",
      "Sixteen new antiepileptic drugs (AEDs) have been approved for the treatment of epilepsy since the\n",
      "late 1980s.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797426, 'ch03')\n",
      "The incidence of acute cholecystitis is approximately the same in the USA and Europe . The exact worldwide incidence is not known but will mirror the\n",
      "rates of gallstone disease . Diagnosis is through laboratory tests and imaging . Figure 3.4 shows a diagnostic algorithm for acute cholecystitis .\n",
      "Symptoms and signs include pain or tenderness and guarding in the right upper quadrant, nausea and vomiting, fever, fast pulse (tachycardia) and a\n",
      "positive Murphy's sign (transient cessation of breathing due to pain during inspiration while the right upper quadrant is palpated, but not the left\n",
      "upper quadrant) . Complications include empyema, perforation of the gallbladder, liver abscess and emphysematous cholecystitis . An inflamed and\n",
      "distended gallbladder may obstruct the main bile duct by pressure from a gallstone causing obstructive jaundice (Mirizzi's syndrome) . Laboratory\n",
      "tests . Leukocytosis and mild elevation in serum bilirubin and transaminases may be present . Transabdominal ultrasonography is the most useful test\n",
      "for acute cholecystitis as it establishes the presence of gallstones (Figure 3.5) . A thickened gallbladder wall (> 4 mm) and pericholecystic fluid\n",
      "are highly suggestive of acute cholecystitis (Figure 3.6) . Sonographic Murphy's sign (tenderness over the gallbladder from the ultrasound transducer\n",
      "during imaging) is also diagnostic . Radionuclide scanning is a useful test if ultrasound is non-diagnostic or inconclusive but there is clinical\n",
      "suspicion of acute cholecystitis . A Tc-HIDA (hepatobiliary iminodiacetic acid) scan uses a technetium-labeled analog of iminodiacetic acid . Non-\n",
      "visualization of the gallbladder with visualization of the tracer in the CBD and the small intestine is consistent with cystic duct obstruction . This\n",
      "test is about 95% accurate for the diagnosis of acute cholecystitis . Computed tomography is useful for identifying local complications of acute\n",
      "cholecystitis (Figure 3.7) . Medical treatment of acute cholecystitis involves . nothing by mouth . intravenous fluids . intravenous antibiotics .\n",
      "Surgical treatment . The definitive treatment is cholecystectomy, which is usually performed laparoscopically, although conversion to open\n",
      "cholecystectomy may be needed . Comparative studies of immediate (within 24-48 hours) versus delayed (after 6 weeks) laparoscopic cholecystectomy show\n",
      "similar rates for success, complications and conversion to open procedure . However, early laparoscopic cholecystectomy decreases hospital stay and\n",
      "medical costs . Subtotal cholecystectomy is sometimes needed if there is extensive inflammation and fibrosis around the gallbladder, making dissection\n",
      "more difficult and higher risk . Prognosis and follow up . Uncomplicated acute cholecystitis has an excellent prognosis, with resolution of symptoms\n",
      "during medical treatment, followed by surgery . Cases complicated by perforation and bile peritonitis have a reserved prognosis, as they require\n",
      "urgent surgery . Chronic cholecystitis . Etiology and pathogenesis . Gallstones are the causative agent in the majority of patients with chronic\n",
      "cholecystitis . Recurrent or chronic obstruction of the cystic duct results in chronic inflammation of the gallbladder wall, which may lead to a non-\n",
      "functioning gallbladder . There is a small, long-term risk of developing gallbladder cancer . Epidemiology and risk factors . Chronic cholecystitis is\n",
      "generally caused by repeated milder attacks of acute calculous cholecystitis or by mechanical irritation of the gallbladder wall by gallstones . These\n",
      "cause the wall of the gallbladder to thicken . The gallbladder begins to shrink, and is subsequently less able to concentrate, store and release bile\n",
      ". The disease occurs more often in women than in men and is more common after 40 years of age . Symptoms and signs include right upper quadrant and\n",
      "epigastric pain . Pain may be episodic and recurrent without the clinical features of acute cholecystitis, but constant right upper quadrant or\n",
      "epigastric pain is the more usual pattern in patients with chronic cholecystitis .\n",
      "\n",
      "Prediction:\n",
      " The incidence of acute cholecystitis is approximately the same in the USA and Europe. Diagnosis is\n",
      "through laboratory tests and imaging. Complications include empyema, perforation of the gallbladder\n",
      "and liver abscess. The disease occurs more often in women than in men and is more common after 40\n",
      "years of age.\n",
      "\n",
      "Reference:\n",
      "Transabdominal ultrasound is the imaging test of choice, with an accuracy of over 95%, for the\n",
      "diagnosis of gallstones in either acute or chronic cholecystitis. A Tc-HIDA (hepatobiliary\n",
      "iminodiacetic acid) scan is 95% accurate for the diagnosis of acute cholecystitis.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797907, 'chp2')\n",
      "Epidemiology and etiology . Despite being the best studied of the glycolytic enzyme disorders, gaps remain in our understanding of pyruvate kinase\n",
      "(PK) deficiency . More than 600 cases of PK deficiency have been reported, mainly from Europe, the USA and Japan, but the disease occurs worldwide,\n",
      "and it is likely that many cases go unreported . This may be because affected individuals die before birth, or because cases are mild and do not\n",
      "require medical attention . Alternatively, some cases may not be properly recognized, or they may be misdiagnosed . Given that some cases may not\n",
      "present with any of the findings usually associated with the condition, there are likely to be more cases of PK deficiency than are published in the\n",
      "literature . Patient registries have now been developed for PK deficiency, which are helping to characterize the range of symptoms and complications\n",
      "arising from this disorder . Prevalence of pyruvate kinase deficiency . PK deficiency occurs equally in men and women . A study in northern England\n",
      "observed a prevalence of 3.3 cases of PK deficiency per million in a mainly white population . Gene frequency studies have estimated the prevalence of\n",
      "PK deficiency in the general white population to be 51 cases per million . In Germany and the USA, it has been estimated that about 1% of the\n",
      "population are heterozygous for PK deficiency, while a study from Hong Kong found that 3% of newborn infants were heterozygous for a particular PK\n",
      "variant . Because PK deficiency is an autosomal recessive disorder, individuals who are heterozygous for a single PK mutation will not show clinical\n",
      "signs of hemolysis or anemia . For this reason, prevalence estimates based on the observation of clinically affected patients will be substantially\n",
      "lower than those based on the prevalence of heterozygotes in a population . The Amish community in Pennsylvania, USA, has a particularly high\n",
      "frequency of PK deficiency, associated with one specific mutation, which can be traced back to a single immigrant couple . An increased incidence has\n",
      "also been reported in children from a polygamist community in the western USA, again associated with a particular mutation . Mutations associated with\n",
      "pyruvate kinase deficiency . As discussed in Chapter 1, mutations in the PKLR gene on chromosome 1 are responsible for PK deficiency . More than 300\n",
      "different mutations have been reported; most are very rare, occurring only once . Currently, about 25% of patients diagnosed with PK deficiency appear\n",
      "to have a previously unrecorded mutation . Although many of the mutations associated with PK deficiency are rare, a few are recorded more frequently\n",
      "(Table 2.1) . The variability in how PK deficiency manifests is thought to reflect the heterogeneity of these causative mutations, as well as the fact\n",
      "that most individuals with PK deficiency will be compound heterozygotes (id est they will have a different mutation in each copy of the PKLR gene) .\n",
      "Approximately 70% of the mutations associated with PK deficiency are missense (M) mutations (id est a single nucleotide change resulting in the\n",
      "production of a different amino acid), while the others are more disruptive non-missense (NM) mutations - either nonsense or insertional mutations,\n",
      "deletions (such as the deletion of exon 11 found in the Romany population), or splicing abnormalities (see pages 43 -) . Genotype-phenotype\n",
      "relationship . Current research is focusing on the relationship between specific mutations in the PKLR gene and the severity of hemolysis . Given the\n",
      "sheer number of different mutations and the predominance of compound heterozygotes, studies of the relationship between genotype and phenotype have\n",
      "grouped patients by type of mutation (id est two missense mutations [M/M], one missense and one non-missense mutation [M/NM], or two non-missense\n",
      "mutations [NM/NM]) . Findings so far suggest that individuals with more disruptive (non-missense) mutations are more severely affected; they have\n",
      "lower levels of hemoglobin and require more frequent transfusions and a greater total transfusion volume . They also have a higher rate of splenectomy\n",
      "and a higher frequency of iron overload (see pages 43 -) . Acquired pyruvate kinase deficiency . While almost all cases of PK deficiency are inherited\n",
      "and result from mutations in the PKLR gene, an acquired form of the deficiency can very rarely occur secondarily to other blood diseases, such as\n",
      "acute leukemia, myelodysplastic syndrome and refractory sideroblastic anemia . Acquired PK deficiency can also result from complications associated\n",
      "with chemotherapy .\n",
      "\n",
      "Prediction:\n",
      " More than 600 cases of pyruvate kinase (PK) deficiency have been reported, mainly from Europe, the\n",
      "USA and Japan. PK deficiency occurs equally in men and women. The Amish community in Pennsylvania,\n",
      "USA, has a particularly high frequency of PK deficiency.\n",
      "\n",
      "Reference:\n",
      "About one quarter of patients diagnosed with PK deficiency will have a previously unrecorded\n",
      "mutation in the PKLR gene.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797105, 'ch05')\n",
      "Developmental theories and environmental factors . Is schizophrenia a degenerative brain disorder, as originally thought by Kraepelin, or is it better\n",
      "viewed as non-progressive? . During the 1990s, much attention was given to the 'neurodevelopmental hypothesis' of schizophrenia . On the basis of the\n",
      "range of observations outlined in Table 5.1, it was suggested that a static lesion, either genetic or environmental in origin during brain\n",
      "development, expressed its effects as a function of the maturational stage of the brain . In schizophrenia, the characteristic symptoms emerge only\n",
      "during the final stages of brain development in adolescence, when normal 'pruning' or elimination of excess synapses takes place . It is now known\n",
      "that schizophrenia results in part from a developmentally regulated disconnection of higher order association areas, through alterations in neuronal\n",
      "migration, synapse formation and myelination . Neurodevelopmental risk factors . Some established risk factors act early in life (Table 5.2) .\n",
      "Obstetric complications generally appear to increase the risk of schizophrenia . During pregnancy, risk factors include rubella and influenza\n",
      "infections in the first or second trimester and antepartum bleeding . Asphyxia and low birth weight, especially with intrauterine growth retardation,\n",
      "are risk factors at birth, as are certain brain insults and infections in childhood . Early developmental delays . Longitudinal follow-up studies of\n",
      "large birth cohorts have shown that the 1-2% of the sample who go on to develop adult schizophrenia show slight delays in motor, speech and\n",
      "intellectual milestones compared with the rest of the cohort . These differences are subtle, such as walking being delayed by 1-2 months . Certain\n",
      "problems, such as developmental receptive language disorders, are particularly linked to later schizophrenia . These developmental delays do not occur\n",
      "in bipolar disorder . Secondary schizophrenias . The so-called secondary schizophrenias fit less easily into the neurodevelopmental formulation . The\n",
      "psychotic symptoms in these cases appear to be caused by a primary organic disorder, either a known physical disorder or a clinically unsuspected\n",
      "brain lesion . Table 5.3 lists those medical conditions in which a clear or possible association with schizophrenia-like disorders has been reported .\n",
      "Antineuronal cell surface antibody disorders involving the N -methyl- D -aspartate (NMDA) receptor can present with psychosis, which responds to\n",
      "immunotherapy . These disorders are more common than previously realized, accounting for perhaps 2-3% of first-onset cases . Clinically recommended\n",
      "screening investigations for first-episode schizophrenia are outlined in Table 5.4 . Street-drug use . Use of cannabis and amphetamine-like drugs has\n",
      "long been known to be an important trigger of relapse, but had not been thought to directly cause the onset of illness . However, several cohort\n",
      "studies since 2000 have shown that use of cannabis doubles the risk of developing schizophrenia . The risk is further increased if minor psychotic\n",
      "symptoms pre-exist and if cannabis use starts early in adolescence . Research suggests that this effect of cannabis may be mediated by a particular\n",
      "gene . Those with a specific version of the catechol- O -methyltransferase (COMT) gene, carried by about a quarter of the general population, appear\n",
      "to be especially prone to psychosis after cannabis use . Delta-9-THC, the active component of cannabis, disrupts learning and recall in schizophrenia\n",
      ". Psychosocial risk factors . There is emerging evidence for the role of non-biological risk factors in schizophrenia, such as the effects of urban\n",
      "upbringing and of ethnicity, as noted in Chapter 3 .\n",
      "\n",
      "Prediction:\n",
      " Is schizophrenia a degenerative brain disorder, as originally thought by Kraepelin, or is it better\n",
      "viewed as non-progressive? During the 1990s, much attention was given to the 'neurodevelopmental\n",
      "hypothesis' of schizophrenia. It is now known that schizophrenia results in part from a\n",
      "developmentally regulated disconnection of higher order association areas.\n",
      "\n",
      "Reference:\n",
      "Cannabis use increases the risk of schizophrenia as well as relapse.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541680, 'ch_4')\n",
      "Cardiometabolic consequences . Overweight/obesity as a whole predisposes to, or is associated with, numerous cardiac complications such as coronary\n",
      "heart disease (CHD), atrial fibrillation, heart failure and sudden cardiac death as a result of abnormalities in blood glucose, lipids, blood\n",
      "pressure, coagulation and inflammation . Independent of any of the other known cardiometabolic risk factors, obesity is associated with hypertension,\n",
      "tachycardia, left ventricular hypertrophy, increased collagen deposition, reduced cardiac contractility and increased end-diastolic pressure . The\n",
      "major circulatory complications are increased total and pulmonary blood volume, high cardiac output and elevated left ventricular end-diastolic\n",
      "pressure . Metabolic syndrome . 'Metabolic syndrome' describes the clustering in an individual of risk factors for cardiovascular disease and\n",
      "diabetes, namely abdominal obesity (Figure 3.1), abnormal glucose metabolism, dyslipidemia and hypertension . The International Diabetes Federation\n",
      "(IDF) updated the definition of metabolic syndrome in 2005, making abdominal obesity a requirement for a diagnosis of the metabolic syndrome, and\n",
      "providing different obesity cut-off points for different ethnic groups . This definition takes account of the fact that central adiposity is common to\n",
      "each component of the metabolic syndrome . The criteria are summarized in Table 3.1 . An estimated 20-30% of middle-aged individuals living in\n",
      "industrialized countries may be affected by the syndrome . According to some estimates, as many as 75 million people in the USA alone may exhibit the\n",
      "syndrome . Others suggest that as few as 30% of adults exhibit none of the major characteristics of metabolic syndrome . Metabolic syndrome is\n",
      "commonly a precursor of type 2 diabetes mellitus and cardiovascular disease, as well as many other associated conditions . Patients with metabolic\n",
      "syndrome are three times more likely to experience a heart attack or stroke than people without the syndrome, and are twice as likely to die as a\n",
      "result . They also have a fivefold greater risk of developing type 2 diabetes mellitus . Definition of the metabolic syndrome is of value because it\n",
      "ensures that any patient with a single cardiovascular risk factor, including obesity, is screened for the others, as their presence is statistically\n",
      "highly likely and coexistent cardiometabolic risks multiply the overall risk . It also ensures that a patient with multiple risk factors, even those\n",
      "considered borderline, is managed as a high-risk individual . The aim of management is to tackle the syndrome as a whole, and obesity in particular .\n",
      "Management of single or even multiple cardiometabolic risk factors, for example hypertension or hyperlipidemia alone, or even the combination of\n",
      "hyperlipidemia, hyperglycemia and hypertension, is insufficient; the fundamental issues of excess and pathologically distributed body fat, exercise\n",
      "deficiency and a nutritionally poor diet require attention . Not all commentators support the utility of the metabolic syndrome as a concept, and the\n",
      "many published definitions and criteria have served to confuse rather than inform . In addition, many other conditions with shared etiology, such as\n",
      "polycystic ovary syndrome (PCOS; see Polycystic ovary syndrome) and non-alcoholic steatohepatitis (NASH; see Liver and gastrointestinal disorders),\n",
      "which are characterized by insulin resistance and excess and/or ectopic fat, are associated with increased cardiometabolic risk even though the\n",
      "criteria for the metabolic syndrome may not be met . Insulin resistance is the common denominator for all the risk factors for metabolic syndrome .\n",
      "Insulin, produced by the beta cells of the pancreas, controls the uptake, intracellular utilization and storage of glucose, amino acids and fatty\n",
      "acids, while inhibiting catabolic processes such as the breakdown of glycogen, fat and protein . A major function is to stimulate the uptake of\n",
      "glucose by skeletal muscle, where it is used as a source of energy . Insulin also has separate functions on adipose tissue, where it inhibits\n",
      "lipolysis - the breakdown of triglycerides - which releases fatty acids into the bloodstream . Individuals with metabolic syndrome have parallel\n",
      "insulin resistance in both muscles and adipose tissue, so in addition to the high insulin and glucose levels, the concentration of circulating fatty\n",
      "acids and dyslipidemia is also high . Insulin resistance occurs when the tissues respond sluggishly to its action, causing blood glucose to rise,\n",
      "requiring more insulin to be produced to compensate - hyperinsulinemia . In the early stages of insulin resistance these physiological changes\n",
      "stimulate increased production of insulin, keeping glucose levels under control; with time, however, the feedback mechanisms become disrupted, glucose\n",
      "levels rise and type 2 diabetes mellitus ensues . Effects of insulin resistance on other organs . Only the insulin receptors in liver, muscle and\n",
      "adipose tissue are abnormal in patients with insulin resistance; the other organs of the body have normal sensitivity but become overstimulated\n",
      "because of the high circulating levels of insulin, leading to further complications of metabolic syndrome .\n",
      "\n",
      "Prediction:\n",
      " An estimated 20-30% of middle-aged individuals living in industrialized countries may be affected\n",
      "by the syndrome. Patients with metabolic syndrome are three times more likely to experience a heart\n",
      "attack or stroke than people without the syndrome. They also have a fivefold greater risk of\n",
      "developing type 2 diabetes mellitus.\n",
      "\n",
      "Reference:\n",
      "Obesity significantly affects cardiometabolic status and risk.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541024, 'ch_12')\n",
      "Brain tumor syndromes and tumor-like cysts . Familial brain tumor syndromes . The vast majority of primary brain tumors occur sporadically, but a\n",
      "small number appear to be familial . The etiology of sporadic brain tumors is unknown, but environmental factors are suspected . Most patients with a\n",
      "family history of primary brain tumors have a hereditary disease that is known to be associated with such tumors, such as tuberous sclerosis,\n",
      "neurofibromatosis, familial polyposis or Li-Fraumeni syndrome . However, some patients do not have any underlying or obvious hereditary disorder that\n",
      "would predispose them to primary brain tumors, but nevertheless give a striking history of these tumors in first-degree relatives . Usually, the\n",
      "tumors are found to be high-grade gliomas . Although it is feasible that germline abnormalities could lead to the development of primary brain tumors\n",
      "in these families, there are a number of unusual demographic features suggesting an environmental rather than genetic explanation for brain tumor\n",
      "clustering . Most cases of confirmed familial cancers are multigenerational, and affected individuals are younger than average for the tumor .\n",
      "However, brain tumor families who do not have one of the recognized hereditary diseases usually involve parent-child and sibling-sibling cases; it is\n",
      "rare for more than two generations to be involved . In addition, the demographics suggest environmental rather than genetic causes in the parent-child\n",
      "and sibling-sibling clusters . These observations suggest that familial exposure to an environmental toxin or ionizing radiation may account for the\n",
      "clustering of primary brain tumors in these families . It is important for clinicians to enquire about any family history of brain tumors, and to be\n",
      "aware of the major syndromes with neoplastic manifestations in the nervous system, so that these diagnoses are not missed . Recognizing a familial\n",
      "brain tumor syndrome is valuable for appropriate patient surveillance for another occult brain tumor or associated disease, for screening family\n",
      "members, and for genetic counseling . Most patients presenting with primary brain tumors will, however, be sporadic cases and the etiology will remain\n",
      "unknown . Neurofibromatosis type 1 is an autosomal dominant disorder with an estimated incidence of 1 in 3500 . However, this disease can occur\n",
      "sporadically, with up to 50% of cases arising as spontaneous mutations . The gene responsible for this disorder, NF1, is located on chromosome 17q12\n",
      "and encodes a protein, neurofibromin, important in intracellular signaling . Diagnosis requires the presence of two or more of the following features\n",
      ". six or more café au lait spots . two or more neurofibromas or one plexiform neurofibroma . axillary or inguinal freckling . optic nerve glioma .\n",
      "characteristic osseous lesions . a first-degree relative with neurofibromatosis type 1 . The major neoplastic neurological manifestations of this\n",
      "disorder are optic nerve glioma, astrocytoma and glioblastoma . The main non-neoplastic neurological features are seizures, cognitive impairment and\n",
      "hydrocephalus (Figure 11.1) . Neurofibromatosis type 2 is an autosomal dominant disorder with an estimated incidence of 1 in 40 000 . The gene\n",
      "responsible for this disorder, NF2, is located on 22q12 . This gene codes for a protein known as merlin or schwannomin that is thought to have a tumor\n",
      "suppressive function . Approximately half of all cases of neurofibromatosis type 2 are due to spontaneous genetic mutations . For a diagnosis of\n",
      "neurofibromatosis type 2 to be made, specific features must be identified . bilateral vestibular hamartomas, or . a first-degree relative with\n",
      "neurofibromatosis type 2, in combination either with a unilateral vestibular schwannoma or with at least two of the following: meningioma, glioma,\n",
      "schwannoma, neurofibroma, posterior subcapsular lens opacity or cerebral calcification, or . two of the following . unilateral vestibular schwannoma .\n",
      "multiple meningiomas . any one of schwannoma, neurofibroma, glioma, posterior subcapsular lens opacity or cerebral calcification . The major\n",
      "neoplastic neurological manifestations are schwannoma, meningioma, astrocytoma, ependymoma and glial hamartoma, while the principal non-neoplastic\n",
      "neurological manifestation is cerebral calcifications (Figure 11.2) .\n",
      "\n",
      "Prediction:\n",
      " The vast majority of primary brain tumors occur sporadically, but a small number appear to be\n",
      "familial. The etiology of sporadic brain tumors is unknown, but environmental factors are suspected.\n",
      "Most cases of confirmed familial cancers are multigenerational and affected individuals are younger\n",
      "than average for the tumor.\n",
      "\n",
      "Reference:\n",
      "There are several syndromes associated with an inherited predisposition to a variety of brain\n",
      "tumors. However, the vast majority of brain tumors are not inherited.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797211, 'ch04')\n",
      "The main aims are to . keep the drug regimen as simple as possible . aid adherence . reduce the likelihood of side effects . Theoretically, attempts\n",
      "should be made to stick to a regimen that mimics CDS as much as possible . Long-acting agents, or continuous delivery systems such as the rotigotine\n",
      "transdermal patch, or controlled-release preparations of other non-ergot dopamine agonists may be particularly useful in this regard . It is very\n",
      "important that the patient's lifestyle, amount of support at home and individual preferences are all taken into consideration, and that the different\n",
      "therapeutic options with their potential side effects and advantages are explained . Modern management of Parkinson's disease is not possible without\n",
      "the support of a multidisciplinary care team . A typical multidisciplinary team should consist of a Parkinson's disease nurse specialist, a\n",
      "physiotherapist, occupational therapist, and an experienced speech and language therapist with access to neuropsychology and palliative care . Current\n",
      "guidelines . Different international guidelines (NICE, AAN, EFNS/MDS-ES) all agree that there is no single universal first choice of drug for people\n",
      "with Parkinson's disease, particularly in the early stages of the condition . Individual choice of drug will be influenced, for example, by the degree\n",
      "of motor disability (if severe, the first choice is likely to be levodopa), occupational needs, the risk of motor complications (more common in\n",
      "younger patients, which would be delayed by agonists), neuropsychiatric complications (more common in older and cognitively impaired patients, so\n",
      "agonists should be avoided), patient/clinician preferences and adherence issues . For these reasons, many younger patients will choose a levodopa-\n",
      "sparing strategy, while older patients may prefer levodopa therapy (see below) . Guidelines for the management of Parkinson's disease published in the\n",
      "UK by NICE in June 2006 offer evidence-based advice drawn up by a multidisciplinary panel . Key recommendations are that patients and their carers\n",
      "should be involved in deciding their treatment and care, and that the choice of treatment should suit the patient's needs and preferences . This\n",
      "guideline is currently being updated . The following key points were identified as priorities for implementation . Any patient with a suspected\n",
      "diagnosis of Parkinson's disease should be seen by a specialist within 6 weeks after referral by the primary care physician . A specialist is defined\n",
      "as an individual with expertise in the differential diagnosis of Parkinson's disease . The diagnosis of Parkinson's disease should be reviewed every\n",
      "6-12 months . The apomorphine and levodopa challenge tests should not be used to differentiate Parkinson's disease from atypical parkinsonian\n",
      "syndromes . Regular access to specialist nursing care, physiotherapy, occupational therapy, and speech and language therapy should be available to\n",
      "patients . Patients and their carers should be given an opportunity to discuss palliative care issues . No specific agents could be identified as the\n",
      "treatment of choice in either early or advanced disease . The guidelines also emphasize the need for considering non-motor symptoms at all stages of\n",
      "Parkinson's disease . Guidelines for the management of Parkinson's disease in other countries are broadly similar to the NICE guidelines . They\n",
      "include those of the AAN, published in 2002 and modified in 2006, and those issued by the joint task force of the EFNS and the Movement Disorder\n",
      "Society's European Section in 2006 . More recent guidelines from the Scottish Intercollegiate Guidelines Network (SIGN) highlight the following issues\n",
      "as key to the modern 'holistic' treatment of Parkinson's disease . communication throughout disease progression . attitudes to drug treatment .\n",
      "information needs in relation to multifaceted areas . family carers' needs . non-motor symptoms . importance of multidisciplinary team working . The\n",
      "SIGN's suggested scheme for therapy is shown in Figure 4.5 . Dopamine agonist versus levodopa . In younger patients, the issues of neuroprotection and\n",
      "dyskinesias should be considered . The results of four controlled dopamine-agonist monotherapy trials have been published and suggest that initiation\n",
      "of treatment with an agonist is beneficial in the early stages of Parkinson's disease . However, the results of the PD Med study, a multicenter real-\n",
      "life pragmatic study, reporting on quality of life-related outcomes in both young and old patients with Parkinson's disease, is likely to generate\n",
      "considerable controversy regarding the use of dopamine agonists and the choice of initial therapy . In total, 1620 patients with early Parkinson's\n",
      "disease were recruited and given one of three initial treatment regimens . levodopa formulation (528 patients) . levodopa-sparing strategy - dopamine\n",
      "agonist (632 patients) .\n",
      "\n",
      "Prediction:\n",
      " The main aims are to. keep the drug regimen as simple as possible. aid adherence. reduce the\n",
      "likelihood of side effects. Theoretically, attempts should be made to stick to a regimen that mimics\n",
      "CDS as much as possible. Modern management of Parkinson's disease is not possible without the\n",
      "support of a multidisciplinary care team.\n",
      "\n",
      "Reference:\n",
      "The treatment of non-motor symptoms is important at all stages of Parkinson's disease. The results\n",
      "of the PANDA study may help people with Parkinson's-associated pain.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781908541963, 'chapter5')\n",
      "Flares in disease activity occur in patients on stable long-term therapy and after reductions in drug dose . These flares are treated in a similar way\n",
      "to newly diagnosed disease . Liver transplantation is an effective therapy for advanced disease . AIH recurs in up to 40% of cases but is generally\n",
      "easily controlled by inclusion of a higher dose of corticosteroids in the maintenance immunosuppression regimen . Primary biliary cirrhosis . PBC is a\n",
      "progressive disease with an asymptomatic phase that may last for 15-20 years . The asymptomatic phase is being increasingly recognized, however, with\n",
      "the detection of increased alkaline phosphatase levels on routine blood tests . The diagnosis is effectively established by the detection of positive\n",
      "antimitochondrial antibodies (AMA), usually of the M2 subtype . The IgM fraction of the serum gammaglobulins is normally raised . The combination of\n",
      "elevated alkaline phosphatase, positive AMA and elevated IgM is now considered diagnostic of PBC; histological verification is no longer necessary .\n",
      "However, a liver biopsy may be of value in staging the severity of the disease . Clinical features . The first symptoms are usually pruritus (itch)\n",
      "and lethargy (tiredness) . The cause of the itch is unclear, but it responds in many cases to therapies that deplete bile salts (exempli gratia\n",
      "colestyramine [cholestyramine]) . Antihistamines are not effective in this situation . The therapies used to treat the pruritus are listed in Table\n",
      "5.2 . The cause of the lethargy is also unclear, but there is increasing evidence to suggest that it is 'central' and secondary to changes within the\n",
      "brain . Hypothyroidism develops in up to 20% of patients with PBC, so it is important to screen regularly for this as a cause of the lethargy . The\n",
      "development of jaundice indicates that the disease is entering the final stage, which lasts for 3-5 years . The prolonged cholestasis leads to\n",
      "cholesterol deposition in the skin (xanthomas and xanthelasma) and osteopenia or osteoporosis (Figure 5.2) . At this stage, patients may also exhibit\n",
      "signs of portal hypertension, with ascites and esophageal or gastric varices . Encephalopathy is less common than in other causes of end-stage chronic\n",
      "liver disease . There is no curative medical therapy for PBC . There is some evidence to support treatment with ursodeoxycholic acid (UDCA), as this\n",
      "improves the biochemical profile and possibly the histological appearance . There is, however, limited evidence that UDCA prolongs survival or delays\n",
      "the need for liver transplantation . A number of other immunosuppressive and antifibrotic therapies have failed to demonstrate sufficient benefit to\n",
      "gain widespread use . Liver transplantation is still the only effective treatment for advanced PBC . The indications for transplantation are liver\n",
      "failure, defined by the Model for End-Stage Liver Disease (MELD) as a disease severity score ranging from 4 to 40, typically above 20; severe and\n",
      "intractable pruritus; and hepatocellular carcinoma The results of liver transplantation for PBC are excellent . There is evidence that PBC recurs in\n",
      "the transplanted liver, but this phenomenon appears to be of little clinical relevance in the first 10-15 years after transplantation . Primary\n",
      "sclerosing cholangitis . PSC can affect all elements of the biliary system .\n",
      "\n",
      "Prediction:\n",
      " Liver transplantation is an effective therapy for advanced disease. PBC is a progressive disease\n",
      "with an asymptomatic phase that may last for 15-20 years. The first symptoms are usually pruritus\n",
      "(itch) and lethargy (tiredness) The cause of the itch is unclear, but it responds in many cases to\n",
      "therapies that deplete bile salts.\n",
      "\n",
      "Reference:\n",
      "Liver transplantation is an excellent treatment for end-stage AIH and PBC.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797426, 'ch03')\n",
      "The mortality for critically ill patients reaches up to 50% . Gallbladder polyps . Etiology and pathogenesis . Gallbladder polyps are seen in about 5%\n",
      "of normal subjects undergoing gallbladder ultrasonography . Differential diagnosis of polypoid lesions of the gallbladder includes cholesterol polyps,\n",
      "adenomyomatosis, inflammatory polyps, adenomas and gallbladder carcinoma . Cholesterol polyps are the result of abnormal deposition of cholesterol and\n",
      "triglycerides into the gallbladder wall . Adenomyomatosis is characterized by thickening of the muscle in the gallbladder wall with overgrowth of the\n",
      "mucosa . Inflammatory polyps are benign non-neoplastic polyps . Adenomas are epithelial growths that can be precursors to gallbladder cancer . The\n",
      "major clinical significance relates to the malignant potential of the polyps . Risk factors that increase the chance of malignancy in a gallbladder\n",
      "polyp include . size > 1 cm . presence of gallstones . age > 60 years . increase in size on interval imaging . Epidemiology and risk factors . In a\n",
      "Scandinavian study the prevalence of gallbladder polyps as assessed by ultrasonography in a random population was 4.6% among men and 4.3% among women\n",
      ". The prevalence of polyps was not significantly associated with age, sex, social or weight factors, physical activity, diabetes mellitus,\n",
      "pregnancies, use of exogenous female hormones, alcohol intake or plasma lipids . However, in a Chinese study of more than 60 000 people, the overall\n",
      "prevalence of gallbladder polyps was 6.9% . Male sex, hepatitis B virus infection and cholecystitis were strong risk factors for the formation of\n",
      "gallbladder polyps . Symptoms and signs . Most patients with gallbladder polyps are asymptomatic, with discovery usually being incidental on imaging\n",
      "studies, although some patients may present with chronic and recurrent biliary-type pain . Transabdominal ultrasonography . Gallbladder polyps are\n",
      "easily visualized . The size and echo features of the polyp(s) assist in differential diagnosis and determination of malignant potential (> 1 cm in\n",
      "size is significantly associated with presence of malignancy) . Cholesterol polyps may be multiple, are usually pedunculated and are hyperechoic, but\n",
      "with no acoustic shadow . Adenomas are usually solitary, sessile and more isoechoic . Computed tomography is not useful for the detection or\n",
      "differential diagnosis of small gallbladder polyps . It is more useful as a preoperative staging technique if malignancy is suspected in a polypoid\n",
      "lesion of the gallbladder . Endoscopic ultrasonography is a more precise modality for gallbladder imaging than transabdominal ultrasound, but is more\n",
      "invasive . Data from a few studies show better differentiation of neoplastic and non-neoplastic polyps . Cholecystectomy is indicated for polyps\n",
      "greater than 1 cm, for polyps with associated gallstones and for patients with biliary symptoms . Solitary sessile polyps that are 5-10 mm in size are\n",
      "more likely to be neoplastic than small, multiple, pedunculated, hyperechoic polyps . Cholecystectomy should be considered if a neoplastic polyp is\n",
      "suspected . Follow-up . Observation with serial imaging is an option for small polyps that are considered to be at low risk for neoplastic features .\n",
      "Polyps that increase in size on serial imaging are an indication for cholecystectomy . Gallbladder carcinoma . Etiology and pathogenesis . Chronic\n",
      "gallbladder inflammation is attributed as an etiologic factor in gallbladder cancer along with molecular alterations in p53 and K-ras . Inflammation\n",
      "may occur as a result of gallstones, gallbladder polyps, chronic Salmonella infection, congenital biliary cysts, abnormal pancreaticobiliary duct\n",
      "junction, carcinogen exposure and certain drugs . There are molecular differences between gallbladder cancers associated with gallstones and those\n",
      "with an abnormal pancreaticobiliary junction . Epidemiology and risk factors . Gallbladder carcinoma is the fifth most common gastrointestinal (GI)\n",
      "cancer in the USA and is the most common GI cancer in Native Americans . Incidence and mortality are very high in certain Latin American countries,\n",
      "especially Chile .\n",
      "\n",
      "Prediction:\n",
      " Gallbladder polyps are seen in about 5% of normal subjects undergoing gallbladder ultrasonography.\n",
      "Cholesterol polyps are the result of abnormal deposition of cholesterol and triglycerides into the\n",
      "gallbladder wall. Inflammatory polyps are benign non-neoplastic polyps. Adenomas are epithelial\n",
      "growths that can be precursors to gallbladder cancer.\n",
      "\n",
      "Reference:\n",
      "Gallbladder cancer is the most common gastrointestinal cancer in Native Americans in the USA and\n",
      "also has a very high incidence in certain Latin American countries, particularly Chile.\n",
      "\n",
      "####################################################################################################\n",
      "\n",
      "(9781910797495, 'chp12')\n",
      "Headache is a common complaint in the general population and one of the most common reasons people seek care from primary care providers . Acute\n",
      "headache . The immediate, important first step in assessing a new headache is determining whether the headache is a serious, potentially life-\n",
      "threatening medical event requiring emergency evaluation and management . All the possibilities highlighted in Table 12.1 must be entertained and\n",
      "discarded before considering the headache to be caused by a chronic headache condition . Brain imaging, including neurovascular studies, may be needed\n",
      "as well as cerebrospinal fluid (CSF) pressure measurement and analysis and further evaluation by a neurologist . Chronic headache . As with all\n",
      "chronic pain, headache must be assessed systematically and classified according to its likely origin as well as its temporal pattern, aggravating and\n",
      "ameliorating factors and perpetuating factors and comorbidities . The headache diagnoses in Table 12.2 should be considered . The history should note,\n",
      "as for any other pain, a general medical history, including a detailed pain history (Table 12.3) . It is important to note whether the headache\n",
      "corresponds to any cycles (menstruation, weekends, circadian) or particular exposures (fumes, smoke, foods, etc) . As emotional factors often trigger\n",
      "tension or migraine headache, psychosocial assessment for the relationship of stressful events to headache onset and extant stressors or psychiatric\n",
      "comorbidities will be important for risk management and treatment planning . Diagnostic testing, particularly brain imaging, may be appropriate .\n",
      "Pathophysiology and associated signs and symptoms . Recent literature has tended to blur what were once thought to be clear distinctions between\n",
      "headaches without a clear anatomic generator, such as tension headache compared with migraine headache . However, it is useful to consider migraine\n",
      "headache and tension headache differently for therapeutic reasons . Migraine headache is now thought to be a condition in which there is cortical\n",
      "neuronal hyperexcitability and/or brainstem dysfunction which activates peripheral nociceptors of the trigeminal neurovascular system . An increase in\n",
      "excitatory neurotransmitters such as glutamate and reduced intracortical inhibition are associated with meningeal inflammation and peripheral\n",
      "sensitization leading to dilation of cerebral vessels and pain . Further activation of the trigeminal nucleus leads to the characteristic signs of\n",
      "central sensitization usually associated with the clinical picture of full-blown migraine, during which almost any sensory stimulus will worsen the\n",
      "headache . These signs and symptoms include allodynia over the face and head, photophobia and sensitivity to noise or movement, causing patients to\n",
      "want to lie down in a dark, completely quiet room until the headache passes . There appears to be a genetic predisposition to migraine in some\n",
      "patients . Tension headache, thought to be due to myofascial pain in the muscles of the head and neck, may be activated by stress and postural\n",
      "factors, or by neural stimuli from an old injury and/or cervical spine disease . These headaches can themselves activate a migraine headache in some\n",
      "patients . Transform headache, often called rebound headache, is caused when the pain-suppressing effects of a short-acting sedative, anxiolytic\n",
      "and/or analgesic wear off so that the manifestations of the sensitized state of the central nervous system (CNS) resumes, often leading to daily\n",
      "headache .\n",
      "\n",
      "Prediction:\n",
      " All the possibilities highlighted in Table 12.1 must be entertained and discarded before\n",
      "considering the headache to be caused by a chronic headache condition. Brain imaging, including\n",
      "neurovascular studies, may be needed as well as cerebrospinal fluid (CSF) pressure measurement and\n",
      "analysis.\n",
      "\n",
      "Reference:\n",
      "In patients without history of chronic headaches, determine whether an acute new headache is a\n",
      "serious, potentially life-threatening condition.\n",
      "\n",
      "####################################################################################################\n",
      "\n"
     ]
    }
   ],
   "source": [
    "print_examples('sshleifer/distilbart-cnn-12-6', df_test)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "hidden": true,
    "id": "Cxcx8xwkJigp"
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "accelerator": "GPU",
  "colab": {
   "collapsed_sections": [
    "P95DxvqWi_2Y",
    "tvSGvNzvKbvP",
    "JFd0ppeJyX1o",
    "dllOnKR9Os5i",
    "U2mpXoSaQiQE",
    "k0qONrX4Qkkm",
    "JiYIkI5xN2VA",
    "KV669nVZQnzT",
    "WIiEnpvbMkJa",
    "fSqOx7kdMoNJ",
    "UTUY8QgQa2WM",
    "bKYnUXhvMszX",
    "mIcAg1ss4qIR",
    "GlnC1NYkRrQH"
   ],
   "name": "assign_bullets_cc.ipynb",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.6.9"
  },
  "widgets": {
   "application/vnd.jupyter.widget-state+json": {
    "05874631cf9342bb92a95ed2e24ff2c7": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_5023d42e4d324b21b7ff374065f4764a",
       "IPY_MODEL_596f45be19214b09824b6f9cfb730862"
      ],
      "layout": "IPY_MODEL_a0de904bd48b4e988b543c90dd08124a"
     }
    },
    "302c0bd9016a4e1fa805350c13c64c59": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_b8e034841ccb45b58759ab6f832bbc23",
       "IPY_MODEL_8facedd6337246f2a54705a0dc7bb9f2"
      ],
      "layout": "IPY_MODEL_df72b63f36934e7bb526a40f3083c21a"
     }
    },
    "6031334cc0ca4091a8ff6fb7637d3229": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_f6b7369a77ac40b1bd5fa59360ec3001",
       "IPY_MODEL_198086d9534b4fe3a61c0a85d8efe9a3"
      ],
      "layout": "IPY_MODEL_c603674f1145412fa7740423630a69fc"
     }
    },
    "942d67e1c23c47f49bad39c135d77104": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_e396cf42ae50407280cb7f7e11f301db",
       "IPY_MODEL_17a3fa9838e34d2c8da953349645d2be"
      ],
      "layout": "IPY_MODEL_c8a2d69848cb4d94b2f50912a4828287"
     }
    },
    "b2332832806b434c92b67aa4fbb169dd": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_485ca68c8ed14c1a96349dbf1d7d07f1",
       "IPY_MODEL_ca55ed72f9974a98b39908d820af46fa"
      ],
      "layout": "IPY_MODEL_9f05edf66a6a44c98517dcb373821ade"
     }
    },
    "faaac5a54b4d4ea0bb61083f9e035cb6": {
     "model_module": "@jupyter-widgets/controls",
     "model_name": "HBoxModel",
     "state": {
      "_dom_classes": [],
      "_model_module": "@jupyter-widgets/controls",
      "_model_module_version": "1.5.0",
      "_model_name": "HBoxModel",
      "_view_count": null,
      "_view_module": "@jupyter-widgets/controls",
      "_view_module_version": "1.5.0",
      "_view_name": "HBoxView",
      "box_style": "",
      "children": [
       "IPY_MODEL_6e66fb3cf50443bda08ef29eb7b75d22",
       "IPY_MODEL_f4c50c858ced49c2bad6e3c78db8028c"
      ],
      "layout": "IPY_MODEL_e45ae0e72241487181d9a3bba2891f2b"
     }
    }
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
